

NAMS POSITION STATEMENT

The 2023 nonhormone therapy position statement of The North American Menopause Society

Abstract

Objective: To update the evidence-based Nonhormonal Management of Menopause-Associated Vasomotor Symptoms: 2015 Position Statement of The North American Menopause Society.

Methods: An advisory panel of clinicians and research experts in women's health were selected to review and evaluate the literature published since the Nonhormonal Management of Menopause-Associated Vasomotor Symptoms: 2015 Position Statement of The North American Menopause Society. Topics were divided into five sections for ease of review: lifestyle; mind-body techniques; prescription therapies; dietary supplements; and acupuncture, other treatments, and technologies. The panel assessed the most current and available literature to determine whether to recommend or not recommend use based on these levels of evidence: Level I, good and consistent scientific evidence; Level II, limited or inconsistent scientific evidence, and Level III, consensus and expert opinion.

Results: Evidence-based review of the literature resulted in several nonhormone options for the treatment of vasomotor symptoms. **Recommended:** Cognitive-behavioral therapy, clinical hypnosis, selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors, gabapentin, fezolinetant (Level I); oxybutynin (Levels I-II); weight loss, stellate ganglion block (Levels II-III). **Not recommended:** Paced respiration (Level I); supplements/herbal remedies (Levels I-II); cooling techniques, avoiding triggers, exercise, yoga, mindfulness-based intervention, relaxation, suvorexant, soy foods and soy extracts, soy metabolite equol, cannabinoids, acupuncture, calibration of neural oscillations (Level II); chiropractic interventions, clonidine; (Levels I-III); dietary modification and pregabalin (Level III).

Conclusion: Hormone therapy remains the most effective treatment for vasomotor symptoms and should be considered in menopausal women within 10 years of their final menstrual periods. For women who are not good candidates for hormone therapy because of contraindications (eg, estrogen-dependent cancers or cardiovascular disease) or personal preference, it is important for healthcare professionals to be well informed about nonhormone treatment options for reducing vasomotor symptoms that are supported by the evidence.

Key Words: Clinical hypnosis – Cognitive-behavioral therapy – Gabapentin – Hormone therapy – Menopause – Nonhormone therapy – Selective serotonin reuptake inhibitors – Serotonin-norepinephrine reuptake inhibitors – Stellate ganglion block – Vasomotor symptoms.

Hot flashes and night sweats (vasomotor symptoms [VMS]) are the most common symptoms of menopause and occur in up to 80% of menopausal women.¹ Vasomotor

symptoms can be bothersome, lasting a mean duration of 7 to 9 years, and in one-third of women, can last more than 10 years.² Hormone therapy (HT) remains the most effective treatment and should be considered in menopausal women aged younger than 60 years, within 10 years of their final menstrual periods, and without contraindications. Despite this, the use of HT has declined substantially after the publication of the Women's Health Initiative (WHI).³⁻⁵ Evidence suggests that contrary to guideline recommendations, younger women and those with more VMS were less likely to receive HT after the WHI than before.⁶ Additionally, rates of continuation of HT have declined in women with more frequent VMS after the WHI, largely because of media reports and provider advice.

Despite the underuse of HT in symptomatic women, some may choose not to use HT or have contraindications to its use, such as a history of an estrogen-sensitive cancer (including breast cancer), coronary heart disease, myocardial infarction,

Received March 21, 2023; revised and accepted March 21, 2023.

This Position Statement was developed by The North American Menopause Society (NAMS) 2023 Nonhormone Therapy Position Statement Advisory Panel consisting of representatives of the NAMS Board of Trustees and other experts in women's health: *Lead*, Chrisandra L. Shufelt, MD, MS, FACP, NCMP; Vivien Brown, MDCM, CCFP, FCFP, NCMP; Janet S. Carpenter, PhD, RN, FAAN; Lisa Astalos Chism, DNP, APRN, NCMP, FAANP; Stephanie S. Faubion, MD, MBA, FACP, NCMP, IF; Hadine Joffe, MD, MSc; Juliana M. Kling, MD, MPH, NCMP, FACP, IF; Claudio N. Soares, MD, PhD, FRCPC, MBA; Rebecca C. Thurston, PhD, FABMR. The NAMS Board of Trustees conducted an independent review and revision and approved the position statement.

This Position Statement was made possible by donations to the NAMS Education & Research Fund. There was no commercial support.

Address correspondence to: The North American Menopause Society; 30050 Chagrin Blvd, Suite 120W; Pepper Pike, OH 44124. E-mail: info@menopause.org. Website: www.menopause.org.

stroke, venous thromboembolism, or inherited high risk of thromboembolic disease.⁷ Nonhormone options are important considerations for women who are not good candidates for HT.

This Position Statement updates and expands information on the nonhormone management of VMS from the 2015 NAMS Position Statement on nonhormone therapies and is intended to provide direction to guide evidence-based nonhormone management of VMS.

METHODS

An advisory panel of clinicians and research experts in the field of women's health was selected to review and evaluate the literature published after the Nonhormonal Management of Menopause-Associated Vasomotor Symptoms: 2015 Position Statement of The North American Menopause Society.

Topics were divided into five sections for ease of review: lifestyle; mind-body techniques; prescription therapies; dietary supplements; and acupuncture, other treatments, and technologies. Individual panel members reviewed and evaluated the evidence on the different therapies for which they had special expertise, with the knowledge that trials of nonhormone treatments of VMS have a placebo improvement rate of 20% to 66%, and women with more anxiety show higher response to placebo.⁸

The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society was written after an extensive review of the pertinent literature and includes key points identified during the review process. The resulting manuscript was submitted to and approved by the NAMS Board of Trustees.

The panel assessed the most current and available literature to recommend or not recommend use with the level of evidence assigned on the basis of these categories:

- Level I: Good and consistent scientific evidence.
- Level II: Limited or inconsistent scientific evidence.
- Level III: Consensus and expert opinion.

This Position Statement uses gender-specific language as reflected in the referenced publications. However, NAMS recognizes that some persons experiencing menopause may identify differently than with the gender and pronouns used in this statement.

LIFESTYLE

Cooling techniques

Hot flashes can be triggered by small, core-body-temperature elevations⁹⁻¹¹; therefore, it is feasible that changing lifestyle practices that control core body temperature may decrease VMS frequency. These include clothing adjustments (ie, dressing in layers; wearing sleeveless blouses; using breathable clothing materials; avoiding pullover sweaters, tops, and scarves) and environmental controls (hand or electric fans; cold packs under the pillow; turning the pillow when feeling warm; dual control electric blankets or a bed fan; lower room temperature). One small (N = 20), uncontrolled trial of postmenopausal women showed benefits with the use of a forehead cooling device and sleep hygiene instructions for reduction in self-reports of sleep problems and VMS over a 4-week period.¹² Another small trial

(N = 39) of a nighttime thermal comfort intervention was studied in a 4-week randomized, crossover trial.¹³ Women reported no objective changes in the number or duration of nighttime VMS with this device, despite some self-reported improvements in sleep compared with baseline (ie, no device). Overall, cooling interventions must be tested in larger randomized, placebo/sham-controlled clinical trials for the treatment of VMS. (Level II; not recommended)

Avoiding triggers

Women are often told to avoid “triggers” such as alcohol, caffeine, spicy foods, or hot foods or liquids. One cross-sectional study of 4,595 Chinese women found a positive association between alcohol intake and VMS¹⁴; however, this has not been reported in other studies (such as the Melbourne Women's Midlife Health Project).¹⁵ There are no clinical trials assessing the effects of avoiding triggers for the alleviation of VMS. (Level II; not recommended)

Exercise and yoga

Observational studies revealed that women who exercise regularly report fewer VMS.¹⁶⁻¹⁸ However, others have found no relationship between level of physical activity or exercise and VMS,¹⁹ and exercise may trigger VMS in symptomatic women.¹⁰ Several *Cochrane* reviews concluded that there was insufficient or poor evidence to consider exercise as a treatment for VMS.²⁰⁻²² Among the challenges, methods and exercise interventions varied widely across studies. They included, for example, supervised walking versus yoga versus no intervention²³ and supervised aerobic exercise versus yoga versus usual activity plus omega-3 or placebo pills.²⁴ No difference was found between yoga and exercise. When study results comparing exercise to no exercise were pooled, exercise had no effect on VMS frequency.²² One study in the *Cochrane* review comparing exercise and HT found that HT was far more effective than exercise in reducing VMS.

A pooled analysis of individual data from four MsFLASH trials (N = 1,005) assessed various interventions compared with placebo for the treatment of VMS, including estradiol, antidepressants, omega-3, cognitive-behavioral therapy (CBT) for insomnia, and yoga or aerobic exercise.²⁵ Women with more bothersome VMS benefited the most from estradiol, whereas those with VMS and insomnia improved with CBT for insomnia. Those with VMS and psychosocial complaints reported improvement with antidepressants or CBT for insomnia. Overall, exercise and yoga led to smaller improvements and were not recommended as single interventions for VMS.

A systematic review and meta-analysis of 12 randomized, controlled trials (RCTs; N = 1,306) assessed yoga against no treatment, health education, exercise, and auricular acupressure for the treatment of VMS.²⁶ Given that all outcomes were self-reported and that there was insufficient blinding of participants, there was a high risk for reporting and detection bias among the studies. Additionally, there was significant heterogeneity in yoga styles, intensity, and frequency, limiting the interpretability of the findings. Yoga had limited benefits compared

with exercise for the treatment of VMS, and there were no benefits compared with no treatment.

Although there are other health benefits associated with exercise or yoga, the evidence of those interventions for the treatment of VMS is sparse. (Level II; not recommended)

Dietary modification

Research evaluating the relationship of diet and VMS is limited. A study in postmenopausal women with more than two VMS per day (N = 84) randomized to a low-fat, plant-based diet and a half-cup of cooked soybeans per day versus no dietary changes found an 88% reduction in moderate to severe VMS compared with a 34% reduction in those with no dietary changes after 12 weeks.²⁷ In surveys, more vegetable and fruit consumption was associated with fewer menopause symptoms,²⁸ and women who followed a vegan diet reported fewer bothersome VMS than those who ate meat. For both, increased vegetable consumption was associated with fewer bothersome symptoms.²⁹ One longitudinal cohort study showed high-fat and -sugar diets were associated with an increased risk of VMS.³⁰ One study found that women who had higher soy milk and vegetable consumption had fewer menopause symptoms, whereas those who ate poultry and skimmed dairy products had worse menopause symptoms overall, including more VMS.³¹ There is limited evidence from clinical trials to support the use of dietary modification for improving VMS. (Level III; not recommended)

Weight loss

Studies have found that women who are obese are more likely to report more frequent and severe hot flashes than women of normal weight.³² Randomized, controlled trials have found that weight loss from behavioral interventions are associated with a decrease in VMS.^{33,34} Additionally, reducing hot flashes was a major motivator for losing weight.³³ Evidence suggests that the role of adiposity and weight loss in VMS may vary depending on age or menopause stage and specifically that adiposity acts as a risk factor for VMS earlier in the transition (perimenopause and early postmenopause)³⁵ but not when women are older or later in the transition.³⁶ Weight loss may have greater effects in reducing VMS when women are earlier in the transition.³³ In an open-label single-arm pilot study of a weight-loss medication (selective serotonin 2C [5-HT_{2C}] receptor agonist) tested in 20 women, after 12-weeks there were both a decrease in weight and significant improvement in VMS (decline, 5.4 hot flashes/d) from baseline to week 12.³⁷ The study also found that after the weight-loss medication was stopped, there was a rapid increase in VMS with a return to baseline weight, further supporting the notion that weight loss improved VMS. However, these studies are either small pilot studies, nonrandomized trials, or post hoc analyses of studies designed for a different purpose. Larger, rigorously designed RCTs are needed. The limited available evidence suggests that weight loss may be used to improve VMS for some women. (Levels II-III; recommended)

Key points

- There is no strong evidence that lifestyle changes such as cooling techniques and avoiding triggers improve VMS.
- There is insufficient or poor evidence to consider exercise or yoga as a treatment for VMS.
- A healthy diet is important for health promotion and chronic disease prevention; however, there is limited evidence to support dietary modifications as a tool for improving VMS.
- Weight loss may be considered for improving VMS.

MIND-BODY TECHNIQUES

Cognitive-behavioral therapy

Cognitive-behavioral therapy (CBT) has been shown to reduce the degree to which VMS are rated as a problem. Initial evidence came from two double-blind RCTs: MENOS 1, which showed that group CBT compared with usual care reduced VMS problem ratings in 96 survivors of breast cancer,³⁸ and MENOS 2, which showed self-guided and group CBT compared with usual care reduced VMS problem ratings in 140 perimenopausal and postmenopausal women without a history of breast cancer.³⁹

A clinical psychologist administered the group CBT intervention, which involved psychoeducation (physiology of VMS; how thoughts and emotions affect the perception of physical sensations), training in relaxation and paced breathing, and cognitive and behavioral strategies to manage VMS (identifying and challenging negative beliefs about VMS; monitoring and modifying triggers of VMS; relaxation exercises). The content of the self-guided CBT was identical to that of the group CBT and included a self-help book completed during a 4-week period, two contacts with a clinical psychologist, weekly homework, and a compact disc for daily practice of relaxation and paced breathing.

The usual-care group received information about VMS, advice on treatment options and symptom management, and instructions for paced breathing and relaxation. In both studies, improvements in VMS problem ratings were maintained at 26 weeks, and more women in the CBT group (65%-78% across studies) reached a clinically significant threshold for improvement in VMS that are rated as a problem than in the usual-care group. Beliefs about coping and control over VMS and beliefs about sleep and night sweats mediated the effect of CBT on VMS problem ratings.⁴⁰

Since these initial trials, several studies have extended this intervention to other modes of delivery and in other populations. Two studies in survivors of breast cancer showed that CBT reduced 1) VMS rated as a problem, hot flash interference, and self-reported VMS frequency when delivered by trained nurses in MENOS 4 (N = 130),⁴¹ or 2) VMS rated as a problem and self-reported VMS frequency when delivered via the internet (with or without therapist support; N = 254).⁴²

A workplace study of 124 menopausal women with problematic VMS found that women who received CBT for VMS using a self-help book had significant reductions in their VMS problem ratings compared with a waitlist control.⁴³ Another study examined CBT in combination with physical exercise in

422 survivors of breast cancer, showing that CBT (with or without exercise), but not physical exercise alone, reduced VMS problem ratings but not VMS frequency compared with a waitlist control.⁴⁴

Finally, a study of 72 perimenopausal and postmenopausal women with VMS and depressed mood found that women randomized to a 12-week group-based CBT intervention had greater reductions in VMS bother and interference⁴⁵ as well as improvements in depressive symptoms than women randomized to a waitlist control. A caveat to this body of work is that the studies largely employ waitlist or usual-care controls, which are less rigorous controls than active controls matched on time and attention. However, the body of literature as a whole supports that CBT alleviates bothersome VMS for both survivors of breast cancer and menopausal women. (Level I; recommended)

Mindfulness-based interventions

Evidence is limited for mindfulness-based interventions (MBI) for the management of VMS. Common features of MBI include instruction in meditation practices and how to approach thoughts, feelings, and bodily sensations in an accepting, nonjudgmental manner. A widely disseminated MBI is mindfulness-based stress reduction (MBSR), a multicomponent intervention that includes mindfulness meditation, body awareness, and yoga.⁴⁶ An RCT of MBSR versus waitlist control was conducted in 110 women who had five or more moderate to severe hot flashes per day. The MBSR intervention was a standardized, widely used, 8-week program involving weekly 2.5-hour group classes, at-home practice (45 min, 6 d/wk), and an 8-hour in-person group retreat. Vasomotor symptoms were assessed via a diary. After 20 weeks, the MBSR group showed greater reductions in hot flash bother (21.62% vs 10.50%; $P = .07$) and intensity (44.56% vs 26.97%; $P = .057$) than waitlist controls; these differences were marginally significant, reflecting the pilot nature of the study, variability in the outcome, and pronounced placebo effect.

Several additional studies have examined MBSR or other MBI for a constellation of menopause symptoms (eg, VMS, anxiety, depressive symptoms, sleep disturbance) in women transitioning through menopause^{47,48} who were survivors of breast cancer⁴⁹ or who had undergone early bilateral oophorectomy.⁵⁰ A meta-analysis similarly examined MBI for quality of life or general menopause symptoms.⁵¹ These studies have generally shown positive effects in reducing menopause symptoms broadly, with mixed effects for VMS specifically. Given that these studies were limited by their small sizes or limited control groups and that they were not designed to consider VMS (eg, women with VMS were not specifically enrolled), there are not enough data to recommend MBSR for the management of VMS. Future rigorously designed trials are needed to test the efficacy of MBI for VMS. (Level II; not recommended)

Clinical hypnosis

Clinical hypnosis is a mind-body therapy that involves a deeply relaxed state and individualized mental imagery and suggestion. It has been widely used to manage other chronic symptoms such as pain and anxiety. Hypnosis has been studied for

the treatment of hot flashes in two trials—one randomized trial in survivors of breast cancer⁵² and one RCT in women with at least seven hot flashes per day.⁵³ In both trials, clinical hypnosis involved 5 weekly in-person sessions of hypnotherapy with at-home self-hypnosis practice. In a study of 60 women with a history of breast cancer, clinical hypnosis was significantly better at reducing hot flashes and improving mood and sleep than no treatment.⁵²

A 2013 single-blind RCT of 187 postmenopausal women reporting at least 50 hot flashes a week at baseline evaluated clinical hypnosis over 12 weeks against an active structured-attention control.⁵³ Both clinical hypnosis and structured-attention control included 5 weekly sessions that included discussion of symptoms, attentive listening, interpersonal exchange, avoidance of negative suggestions, monitoring, measurement, and encouragement provided in a therapeutic environment with a trained clinician. The hypnosis group additionally received hypnotic inductions and cooling suggestions. Participants in the clinical-hypnosis arm reported significantly lower hot flash frequency (74% vs 17%; $P < .001$) and hot flash scores (frequency times severity, 80% vs 15%; $P < .001$) than controls. In addition, physiologically monitored hot flashes were reduced significantly more in the hypnosis group than in the attention-control group (57% vs 10%; $P < .001$), indicating a clinically significant improvement. A follow-up analysis showed that effects were not related to women's expectations about whether hypnosis would work.⁵⁴ The program can be delivered via a trained provider or accessed via a smartphone application. (Level I; recommended)

Paced respiration

Paced respiration is unlikely to provide any benefit for hot flashes. Paced respiration involves taking six to eight slow, deep breaths per minute while inhaling through the nose and exhaling through the mouth. Paced respiration was shown to reduce hot flashes in several small studies that were done in a behavioral laboratory.⁵⁵⁻⁵⁷ Two larger studies did not show any benefits over other forms of breathing. In a randomized trial of 208 women, paced respiration was no better than shallow breathing or usual care for reducing hot flash frequency, severity, bother, or interference.⁵⁸ Similarly, in a randomized trial of 92 women, paced respiration practiced once or twice per day was no better than usual breathing for reducing hot flash scores (frequency times severity).⁵⁹ A third study showed that women who used a chest device to guide their slow, deep breathing practice at home for at least 15 minutes per day had significantly less benefit than a control group assigned to music listening.⁶⁰ (Level I; not recommended)

Relaxation

Evidence is limited and inconsistent on relaxation for hot flashes. A 2014 *Cochrane* review⁶¹ and a 2008 systematic review⁶² both concluded that evidence from RCTs of relaxation was insufficient. There are two studies that were not included in either review. The first was a nonblinded, randomized trial showing a reduction in hot flash frequency with applied relaxation ($n = 33$) compared with a waitlist control group ($n = 27$).^{63,64}

The second was a randomized trial comparing a nine-module, internet-delivered, applied relaxation program to an untreated control group. Of 46 women randomized in a 1:1 fashion, 66% dropped out early (no reasons provided), and the study had to be terminated. Limitations across studies included small sample sizes or lack of an appropriate attention-control group.^{55,56,63,65-68} (Level II; not recommended)

Key points

- CBT has been shown to reduce the bother and interference associated with VMS.
- Clinical hypnosis has been shown to reduce VMS frequency and severity.
- MBSR interventions for the management of VMS are limited by sample size and lack of control groups and are not designed to consider VMS; therefore, there are not enough data to recommend treatment.
- Paced breathing and relaxation techniques do not alleviate VMS and are not recommended.

PRESCRIPTION THERAPIES

Many nonhormone prescription therapies have been evaluated and found to significantly reduce VMS in symptomatic menopausal women. However, there are only two FDA approved for this indication: paroxetine mesylate 7.5 mg daily and fezolinetant 45 mg daily. Other medications that reduce VMS include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentin, and oxybutynin. Typically, the onset of action is within 2 weeks. There are limited trials comparing nonhormone prescription therapies head-to-head with hormone therapy.

Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors

Evidence exists that SSRIs and SNRIs are associated with mild to moderate improvements in VMS, regardless of whether menopause is natural or surgical, as supported by meta-analyses,⁶⁹⁻⁷¹ a pooled analysis,⁷² a *Cochrane* review,⁷³ and a review focused on evidence in survivors of cancer.⁷⁴ Limitations to these reviews include heterogeneity of the populations and variations in inclusion criteria, as well as variability in the population that was tested, dosing, length of treatment, and outcomes evaluated.

Paroxetine,⁷⁵ escitalopram,⁷⁶ citalopram,⁷⁷ venlafaxine,^{78,79} and desvenlafaxine⁸⁰ have been shown to significantly reduce VMS in large, double-blind RCTs of symptomatic women. Duloxetine has been found to reduce VMS in smaller studies.^{81,82} Hot flash reductions vary from 25% to 69% with these treatments, with improvements in composite hot flash severity and frequency from 27% to 61%. Trends toward improvement have been seen with sertraline and fluoxetine, but these were statistically insignificant; therefore, they are not recommended.^{69,79,83-86}

A pooled analysis from three RCTs showed that 10 mg to 20 mg of escitalopram, 0.5 mg of oral 17 β -estradiol, and 75 mg of venlafaxine daily resulted in comparable reductions in VMS frequency. A trial reported that 75 mg per day of venlafaxine was similar to low-dose oral estradiol 0.5 mg per day.^{79,87} Oral estradiol reduced the frequency of hot flashes

by 2.3 more per day than placebo ($P < .001$), whereas venlafaxine reduced the frequency of hot flashes by 1.8 more per day than placebo ($P = .005$). However, neither of these trials allowed dose escalation, in which case estradiol would be expected to provide 77% improvement in hot flashes on average.⁸⁸

A low-dose paroxetine salt (7.5 mg/d) was the first nonhormone pharmaceutical FDA approved for the treatment of moderate to severe VMS, with improvements found in VMS severity and frequency for up to 24 months, along with improvements in sleep disruption, without weight gain or negative effects on libido.^{89,90}

Prior neuroleptic syndrome, serotonin syndrome, and concurrent use of monoamine oxidase inhibitors are contraindications to SSRIs and SNRIs. Caution should be taken in prescribing in patients with uncontrolled seizures, bipolar disorder, kidney or liver insufficiency, uncontrolled hyponatremia, and poorly controlled hypertension, as well as concurrent use of other SSRIs or SNRIs and pertinent polymorphisms in cytochrome P450 enzyme pathways. Black box warnings include uncommon suicidal thoughts in adolescents and children within the first few months.

Coadministration of SSRIs may lead to inhibition of CYP2D6 (the enzyme that converts tamoxifen to its most active metabolite, endoxifen) in women using tamoxifen, particularly with paroxetine and fluoxetine. Safer choices for those on tamoxifen include venlafaxine, desvenlafaxine, escitalopram, or citalopram because they have less of an effect on the CYP2D6 enzyme. There is a possible reported risk of bone fracture with SSRIs because serotonin alters signaling on bone metabolism,^{91,92} although this has not been seen with short-term use.⁹³ They may produce nausea or dizziness, which typically improves after 1 to 2 weeks. (Level I; recommended)

Gabapentinoids

Gabapentin is FDA approved as an antiepileptic drug that is commonly used to treat diabetic neuropathy and postherpetic neuralgia. However, several trials studying the dose of 900 mg (300 mg three times/d) show that this has improved the frequency and severity of VMS.⁹⁴⁻⁹⁶ Possible adverse events (AEs) include dizziness, unsteadiness, and drowsiness, typically seen during the first week, with improvement during the second week and resolution by week 4. In a placebo-controlled trial, higher doses of gabapentin (titrated to 2,400 mg/d) were as beneficial as estrogen (conjugated equine estrogens 0.625 mg/d) in reducing hot flash severity scores.⁹⁷ Adverse events of gabapentin at this dose included dizziness, headache, and disorientation, which limited its potential benefits. Because drowsiness is an AE, and the half-life is short, bedtime dosing of gabapentin may be a good choice for women with disruptive sleep from VMS. Black box warnings for all antiepileptic agents, including gabapentin, include uncommon suicidal thoughts or behaviors. Adverse events include drowsiness, dizziness, and impaired balance or coordination. The suggested dosing (Table 1) for gabapentin is 900 mg to 2,400 mg per day in divided doses. (Level I; recommended)

TABLE 1. Suggested dosing ranges for nonhormone prescription therapies

SSRIs		
Paroxetine salt	7.5 mg	Single dose, no titration needed
Paroxetine	10-25 mg/d	Start with 10 mg/d
Citalopram	10-20 mg/d	Start with 10 mg/d
Escitalopram	10-20 mg/d	Start with 10 mg/d (for sensitive or older women, start with 5 mg/d for titration, but this dose has not been evaluated for efficacy)
SNRIs		
Desvenlafaxine	100-150 mg/d	Start with 25-50 mg/d and titrate up by that amount each day
Venlafaxine	37.5-150 mg/d	Start with 37.5 mg/d
Gabapentinoids		
Gabapentin	900-2,400 mg/d	Start with 100-300 mg at night, then add 300 mg at night, then a separate dose of 300 mg in the morning (start 100 mg if concerned about sensitivity)
Neurokinin B antagonists		
Fezolinetant	45 mg/d	Single dose, no titration needed

SNRIs, serotonin-norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors.

Pregabalin

Pregabalin is a gamma-aminobutyric acid analog structurally related to gabapentin FDA approved for the management of neuropathic pain and seizures. There has been one phase 3 RCT in 163 women (40% with a history of cancer) evaluating pregabalin for VMS.⁹⁸ After 6 weeks of treatment, pregabalin at a dose of 75 mg twice a day or 150 mg twice a day decreased VMS frequency by 59% and 61%, respectively, whereas placebo decreased symptoms by 35%. There were more dizziness and cognitive difficulties reported in those taking pregabalin. Because of limited studies, AEs, including weight gain, and because pregabalin is listed as a Schedule V controlled substance (because of the potential for abuse), pregabalin is not recommended. (Level III; not recommended)

Clonidine

Clonidine is a centrally active α -2 adrenergic agonist that has been shown to be modestly more beneficial than placebo⁶⁹ but less beneficial than SSRIs, SNRIs, and gabapentin in reducing VMS.^{69,73} It is used infrequently because of AEs, including hypotension, lightheadedness, headache, dry mouth, dizziness, sedation, and constipation. Sudden cessation can lead to significant elevations in blood pressure. Because there are other more effective therapies with fewer AEs, clonidine is not recommended. (Levels I-III, not recommended)

Oxybutynin

Oxybutynin is an antimuscarinic, anticholinergic therapy that is used for the treatment of overactive bladder and urinary urge incontinence. One prospective study⁹⁹ and two randomized, double-blind studies^{100,101} in postmenopausal women demonstrated that oxybutynin at doses ranging from 2.5 mg or 5 mg twice daily up to 15 mg extended-release daily significantly improved moderate to severe VMS. Adverse events of oxybutynin are usually dose-dependent and most commonly include a dry mouth and urinary difficulties. Long-term use of anticholinergics may be associated with cognitive decline, particularly in older persons.¹⁰²⁻¹⁰⁴ (Levels I-II; recommended)

Suvorexant

Suvorexant is a dual orexin-receptor antagonist that blocks the effects of the hypothalamic neuropeptide orexin-A, which promotes wakefulness and may be involved in the occurrences

of hot flashes. Postmenopausal women have plasma levels that are three times higher than premenopausal women, which may contribute to sleep disruption and impaired thermoregulation.¹⁰⁵ Suvorexant has been shown to reduce insomnia severity,¹⁰⁶⁻¹⁰⁸ and findings in a small study of menopausal women showed that it led to reductions in nighttime VMS frequency compared with placebo and was well tolerated.¹⁰⁹ Suvorexant did not improve daytime VMS. Given limited data to support its use, suvorexant is not recommended. (Level II; not recommended)

Neurokinin B antagonists

New nonhormone therapies, only one of which (fezolinetant) is FDA approved, are important because their development was founded on the burgeoning understanding of VMS physiology. It is recognized that pulsatile gonadotrophin-releasing hormone (GnRH) secretion is itself driven by an ensemble of pacemaker cells that produce kisspeptin, neurokinin B, and dynorphin, leading to the coined acronym *KNDy* (pronounced *candy*) to describe this unique subset of hypothalamic neurons. These *KNDy* neurons are surrounded by a dense plexus of interconnected fibers to ensure that all *KNDy* neurons fire in concert and together constitute the GnRH pulse generator.¹¹⁰

Neurokinin B stimulates and dynorphin inhibits sustained pulsatile kisspeptin secretion. In turn, kisspeptin acts directly on GnRH neurons to stimulate GnRH secretion, thereby driving luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release. In parallel with the effect of *KNDy* neurons on GnRH in the hypothalamus, the *KNDy* neuronal plexus has direct effects on the adjacent hypothalamic thermoregulatory center.¹¹¹ After declines in circulating levels of estradiol across the menopause transition, VMS are triggered by hyperactivity of the *KNDy* neuron plexus, resulting in hypersecretion of neurokinin B.¹¹² Hypersecretion of neurokinin B from the *KNDy* neurons onto the adjacent thermoregulatory center in the hypothalamus¹¹¹ causes disruption of temperature control and the occurrence of VMS.^{112,113}

Therapeutic development of neurokinin B antagonists was initiated as a novel strategy to target VMS. This nonhormone approach directly targets the neural mechanism underlying VMS. Published results of RCTs are available for three distinct agents, with fezolinetant, which is FDA approved, and elinzanetant¹¹⁴⁻¹¹⁶ in development. A third agent, antagonist (MLE4901),^{117,118,121} is no longer being pursued as a VMS treatment.

Published trial results include demonstration of efficacy of fezolinetant^{116,119,120} and elinzanetant^{116,121} relative to placebo. Fezolinetant is a selective neurokinin B receptor-3 antagonist found to be more beneficial than placebo within and up to 12 weeks of use. Elinzanetant is a dual neurokinin B receptor-3 and receptor-1 antagonist found to be more beneficial than placebo within 2 weeks of use. Phase 3 trials have demonstrated safety, with headache as the most common AE.¹²⁰ Elevation of hepatic enzymes was rare and resolved either during continued treatment or with treatment discontinuation.

The effect of neurokinin B antagonists on other symptoms that commonly co-occur with VMS or are frequently experienced during the menopause transition has received less attention. Early evidence suggests benefit for quality of life- and VMS-related distress, nocturnal awakenings, and sleep quality.^{114-116,119,121-123} Further effect on VMS-related mood and genitourinary, sexual, cardiovascular, metabolic, and bone health are lacking. Higher doses appear to suppress LH but not estradiol in postmenopausal women with VMS.¹¹⁴ However, potentially advantageous and detrimental effects on other physiologic processes have yet to be fully investigated in larger populations.

Key points

- SSRIs and SNRIs are associated with mild to moderate improvements in VMS.
- Gabapentin is associated with improvements in the frequency and severity of VMS.
- Pregabalin is not recommended for VMS because of AEs and controlled-substance prescribing restrictions.
- Because of significant AEs and no recent studies showing greater benefit than placebo, clonidine is not recommended.
- Oxybutynin has been shown to reduce moderate to severe VMS, although in older adults, long-term use may be associated with cognitive decline.
- Given limited data, suvorexant is not recommended.
- Fezolinetant is a first-in-class neurokinin B antagonist that is FDA approved for management of vasomotor symptoms.

DIETARY SUPPLEMENTS

Managing VMS with dietary supplements is complex and challenging because there are limited rigorous randomized, clinical trial data from which to evaluate supplements and a lack of government regulation to ensure their purity and safety. These over-the-counter products remain widely marketed through direct-to-consumer marketing. They are permitted to market toward specific claims of alleviating symptoms despite limited evidence as long as there is no claim to provide disease benefit.

Dietary supplements with limited or inconsistent evidence of benefit

Soy foods and soy extracts

Soy is the most widely used isoflavone-containing food. Isoflavones are a class of phytochemicals, a broad group of nonsteroidal compounds of diverse structure that bind to estrogen receptors (ERs) in animals and human beings. Isoflavones have a greater affinity for ER- β than for ER- α and possess

both estrogen-agonist and estrogen-antagonist properties.¹²⁴ Soy is among the eight most common food allergens,¹²⁵ and reactions can range from mild (eg, bloating, flatulence, loose stools) to severe (eg, anaphylaxis).

“The Nonhormonal Management of Menopause-Associated Vasomotor Symptoms: 2015 Position Statement of The North American Menopause Society” noted mixed evidence for use of soy for VMS.¹²⁶ Soy trials published since 2015 are difficult to summarize because of the wide variation in interventions tested (eg, soy-based drinks,^{127,128} soy isoflavone derivatives in tablets only¹²⁹ or combined with exercise,¹³⁰ or mixed with other supplements [herbals, vitamins, or minerals]), with widely varying dosages tested.¹³¹⁻¹³⁵ These studies also have significant limitations, including small sample sizes,^{129-131,133,134} use of symptom checklists^{126-131,133,135} rather than VMS diaries,¹³⁴ and relatively short-term assessment of outcomes. For example, most participants reported VMS after 12 weeks of treatment,^{127-129,131,133-135} yet meta-analyses suggest more than 13 weeks are needed to demonstrate half of the expected maximal effects,¹³⁶ and more than 16 weeks are needed for optimal effects.¹³⁷ As a result of these study differences and limitations, the findings are mixed, with some studies showing soy to be beneficial for reducing VMS or severity,^{131,132,135} and others showing no benefit of soy over placebo^{127,128,130,133} or finding soy to be less beneficial than other treatments.¹²⁹ (Level II; not recommended)

Soy metabolite equol

Equol is a nonsteroidal estrogen that binds to ER- α and ER- β , but because of its high affinity for ER- β , it is often designated as an ER- β agonist. Few studies have considered whether study participants can metabolize soy, which is critical for soy’s potential estrogenic effects. Only 35% of North American women can metabolize the soy isoflavone daidzein to equol.¹³⁸ Women who are able to metabolize soy into equol would be expected to experience relief from VMS with soy products or equol. Women who cannot produce equol after ingesting soy do not benefit from soy but would be expected to benefit from equol. Tests to ascertain whether women are equol producers are not commercially available to the public or healthcare professionals.

A 2019 systematic review and meta-analysis found positive effects of equol supplementation over placebo for reducing VMS frequency in three of five trials.¹³⁹ Null findings in the remaining two trials were hypothesized to have been because of large differences in VMS at baseline in one trial and inclusion of only equol-producing women in the largest trial. A limitation in most studies (4 of the 6) was inclusion of fewer than 50 participants per group.

There is currently mixed evidence for soy foods, soy extracts, and the soy metabolite equol from widely diverse studies, with some significant limitations. (Level II; not recommended)

Pollen extract

A proprietary extract made from flower pollen has been available under the brand names Relizen, Serelys, Femal, and Femalen. One RCT (N = 53) found that women randomized to receive pollen extract showed significant reductions in VMS on the Menopause

Rating Scale (MRS; 65% VMS reduction with pollen extract vs 38% with placebo, $P < .006$) and daily diaries (27% greater reduction with treatment than placebo, $P < .026$) after 3 months of use.¹⁴⁰ A single-arm multicenter study (N = 104) found a significant decrease in menopause symptoms after 12 weeks' use of pollen extract.¹⁴¹ An additional observational, single-arm study (N = 108) that included perimenopausal and menopausal women found reduction in hot flashes after 3 months' use of pollen extract.¹⁴² However, based on expert opinion and limited scientific research for the management of VMS, pollen extract is not recommended. (Level III; not recommended)

Ammonium succinate

An ammonium succinate-based supplement (Amberen) was studied for the management of menopause symptoms in a manufacturer-sponsored clinical trial, with an initial study published in 2016,¹⁴³ and later a pooled analysis including this study and a second additional study was published in 2019.¹⁴⁴ The studies were identical multicenter, double-blind, 90-day RCTs including women aged 42 to 60 years with mild to moderate menopause symptoms (n = 227). Both studies showed improvement in menopause symptoms such as sleep, fatigue, loss of interest in sex, joint and muscle pain, VMS, and a decrease in anxiety compared with the placebo group. Women in the ammonium succinate-supplement group also showed an increase in serum estradiol levels and a decrease in leptin. The authors concluded that the pooled analysis of the two studies found that the ammonium succinate-based supplement improved menopause symptoms, including VMS, compared with placebo. Because of limited studies and the results being based on manufacturer-sponsored clinical trials, ammonium succinate is not recommended. (Level II; not recommended)

Lactobacillus acidophilus

Lactobacillus acidophilus YT1 was studied for managing menopause symptoms.¹⁴⁵ One 12-week, multicenter, double blind, RCTI (N = 67) involved women with menopause symptoms including VMS. After 12 weeks, total Kupperman Index (KI) scores decreased, and quality of life was improved (Menopause-Specific Quality of Life [MSQOL] questionnaire) in all four symptom domains (physical, psychological, vasomotor, and sexual). There were no reported changes in hormone levels or endometrial lining. Given that this data is limited to one small study, based on global menopause symptom ratings, and has not been replicated, it is not recommended at this time. (Level II; not recommended)

Rhubarb

Siberian rhubarb (*Rheum rhaponticum*) is used as a food and as a medicinal plant for constipation, diarrhea, and other gastrointestinal complaints. A single commercial preparation of rhubarb extract, which has been used in Germany for more than 20 years, was introduced in the United States (Estrovera). The product contains a proprietary extract called *rhaponticin* or extract ERr 731 and contains estrogenic properties but is not estrogen. One study randomized 109 symptomatic perimenopausal women to ERr 731 (n = 54) or placebo (n = 55) daily for 12 weeks.¹⁴⁶ Only

7 of 55 women randomized to placebo completed the trial (12.7% retention rate), and 39 of 54 women randomized to active treatment completed the trial. The researchers reported that at 12 weeks, the MRS total score and each symptom within the scale (including VMS) significantly improved in the active-treatment group versus placebo. Human safety data were drawn from a group of 23 women followed for 48 weeks, 20 of whom completed a 96-week observation period. Few AEs were reported.¹⁴⁷ Another open-label, single-arm study in Indian perimenopausal women over 12 weeks reported improved menopause symptoms.¹⁴⁸ Given the extremely low retention rate in clinical trials and the open-label study design in one study, the conclusions are limited. (Level II; not recommended)

Dietary supplements without demonstrated evidence of benefit

Black cohosh

Black cohosh, scientific name *Actaea racemosa* L. (previously *Cimicifugae racemosae*), is the most purchased botanical for menopause symptoms. The active ingredients in black cohosh extract are unknown, and its mechanism of action is unclear. At one time it was thought to be estrogenic, with in vitro and in vivo assays indicating estrogen-like activity.¹⁴⁹ Other studies indicate activity similar to selective estrogen-receptor modulators¹⁵⁰ or modulation of serotonergic pathways, as well as antioxidant and anti-inflammatory effects.

Reports of possible hepatotoxicity started to appear after 2000. After examining all reported cases, the US Pharmacopeial Convention Dietary Supplements-Botanicals Expert Committee found 30 reports possibly related to black cohosh. The committee issued a directive that black cohosh products carry a warning statement: "Discontinue use and consult a health-care practitioner if you have a liver disorder or develop symptoms of liver trouble, such as abdominal pain, dark urine, or jaundice."¹⁵¹

A 2012 *Cochrane* review¹⁵² analyzed 16 RCTs of 2,027 perimenopausal or postmenopausal women treated with black cohosh using a median daily dose of 40 mg for a mean duration of 23 weeks. There was no significant difference between black cohosh and placebo in the frequency of VMS. Data on safety were inconclusive. Other literature compared black cohosh to HT in a randomized trial of three groups: group A, 1 mg estradiol plus cyclic 4 mg medroxyprogesterone acetate; group B, 1 mg estradiol daily plus cyclic 100 mg micronized progesterone; and group C, 100 mg *Cimicifuga foetida* extract daily.¹⁵³ The study was limited by sample size because only 81 women (84%) completed the study, and although the KI scores were reduced in each group, there were no significant differences between groups. Despite this, the authors concluded that *C foetida* extract could alleviate VMS after 12 weeks. Another large systematic review (35 studies and one meta-analysis) noted that the effects of *C foetida* was possibly dose-dependent as well as augmented when combined with other products such as St. John's wort.¹⁵⁴ At this time, there is insufficient evidence to support the use of black cohosh for VMS. (Level I; not recommended)

Other supplements

Wild yam. *Dioscorea barbasco*, *D mexicana*, and *D villosa* are the varieties of wild yam most commonly used. *D villosa*, also known as Mexican yam or wild yam root, contains diosgenin, a steroid precursor used in the manufacture of synthetic steroids. Diosgenin is converted in vitro to progesterone, but there is no biochemical pathway for this conversion in vivo. Evidence for *Dioscorea* for VMS is limited. One clinical trial employing a yam cream to treat VMS reported no significant benefit.¹⁵⁵ Tested yam creams often do not contain any yam extract, and many have been adulterated with undisclosed steroids, including estrogens, progesterone, and medroxyprogesterone acetate. Because of the potential harm that may result from adulterants and lack of efficacy data, yam creams are not recommended for VMS. (Level II; not recommended)

Dong quai, also known as *Angelica sinensis*, dang gui, and tang kuei, is the root of the *Angelica polymorpha* Maxim var *sinensis* (Oliv). Researchers enrolled 71 women in an RCT of 4.5 g dong quai per day or placebo.¹⁵⁶ After 24 weeks, there were no differences in VMS frequency; KI scores; levels of FSH, LH, or estradiol; vaginal maturation index; or endometrial thickness. Dong quai does not appear to alleviate VMS, and there are a number of safety concerns, including possible photosensitization, anticoagulation, and carcinogenicity. (Level II; not recommended)

Evening primrose, *Oenothera biennis* L, is a flowering plant rich in linolenic acid and γ -linolenic acid. There is a single trial of evening primrose oil for menopause symptoms in which 56 women were randomized to evening primrose oil 500 mg per day or placebo for 6 months.¹⁵⁷ Evening primrose oil did not show benefit over placebo, with VMS declining by 1.0 per day with evening primrose oil and by 2.6 per day with placebo. (Level II; not recommended)

Maca (*Lepidium Meyenii* Walp, *Lepidium peruvianum* Chacon), a traditional foodstuff from South America, contains a weak phytosterol (β -sitosterol) also found in several other botanicals such as saw palmetto. Both methanolic and aqueous extracts of maca exhibit estrogenic activity in vitro, but studies have found no in vivo estrogenic effects. In a systematic review, four studies showed improvements in Greene Climacteric Scale or KI scores. However, because of quality, design, sample sizes, or limited reporting of study data,¹⁵⁸ existing evidence is not strong enough to support the use of maca for VMS. (Level II; not recommended)

Ginseng. There are two distinct true ginsengs in common use; *Panax ginseng* and *Panax quinquefolius*, as well as a third substance, Siberian ginseng (*Acanthopanax senticosus* or *Eleutherococcus senticosus*), a member of a closely related family of plants (Araliaceae). In a study of a specific proprietary product, G115 (Ginsana in the United States), 384 postmenopausal women were randomized to G115 or placebo.¹⁵⁹ After 16 weeks, women taking G115 did not show greater VMS reductions than with placebo. Similarly, researchers found no significant effect of Korean red ginseng on VMS frequency versus placebo.¹⁶⁰ A second study similarly found that ginseng failed to affect VMS when measured by the KI and the MRS.¹⁶¹ Thus,

ginseng does not appear to be beneficial for VMS. (Level I; not recommended)

Labisia pumila/Eurycoma longifolia was studied in a double-blind, 24-week RCT of women aged 41 to 55 years (N = 119) experiencing menopause symptoms (MRS and MSQOL questionnaire used for assessment of symptoms).¹⁶² At week 12, the group randomized to active treatment experienced improvement in symptoms (65%) compared with placebo (60%; $P < .01$). However, at weeks 12 to 24, significant improvement in the MRS and MSQOL questionnaire scores were noted in both treatment and placebo groups ($P < .001$). Overall, the authors concluded that there were no significant differences in menopause symptoms between treatment and placebo groups. (Level I; not recommended)

Chasteberry. Vitex species have estrogenic properties, and compounds such as apigenin and penduletin are their ER- β -selective compounds, whereas rotundifuran and agnuside activate ER- α -dependent responses.¹⁶³ Four double-blind RCTs have tested supplements containing varying amounts of Vitex agnus-castus (an amount equivalent to 1,000 mg dried vitex fruit,^{164,165} 50 mg of vitex fruit extract,¹⁶⁶ or 125 mg vitex fruit¹⁶⁷) in combination with various other supplements¹⁶⁵⁻¹⁶⁷ or combined with *Nigella satvia* and citalopram 20 mg per day.¹⁶⁴ All trials included perimenopausal or postmenopausal women with VMS and included methods to assess compliance. The largest and most rigorous trial (n = 100) compared a mixed supplement to placebo and found no group differences in daily diary VMS frequency or questionnaire VMS intensity after 16 weeks of treatment.¹⁶⁵ The remaining three smaller (<50 women/group) trials used less rigorous questionnaire-only measures of VMS (rather than diaries) and found significant reductions in VMS frequency, bother, or intensity ratings after 8 to 12 weeks of treatment.^{164,166,167} Few AEs were reported in any of the trials. Because of differences in the compounds that were tested, it is not possible to conclude that Vitex alone improves VMS. (Level II; not recommended)

Milk thistle is a member of the Asteraceae family, a therapeutic herb used for fever and kidney and spleen disease. One previous study evaluated its effect in polyherbal formulations that included black cohosh, dong quai, and other herbs. It has been evaluated in a small RCT of 40 women receiving *Silybum marianum* extract and 40 women receiving placebo over a 12-week period and reported improvement in hot flashes and night sweats severity over placebo.¹⁶⁸ Because of the limitations of one study, there is not enough evidence to make a recommendation. (Level II; not recommended)

Omega-3 fatty acid supplements contain polyunsaturated fatty acids, including eicosapentaenoic acid, docosahexaenoic acid, and α -linolenic acid. Phospholipids, a major component of neuronal cells, contain a high prevalence of fatty acids. Two trials have evaluated omega-3s for VMS: In an 8-week trial of 91 women randomized to placebo or omega-3 supplement (total daily dose, 1,100 mg eicosapentaenoic acid plus 50 mg docosahexaenoic acid), VMS frequency and intensity were significantly improved with omega-3 compared with placebo.¹⁶⁹ In a 12-week trial, women were randomized in a 1:1 ratio to

omega-3s (n = 177) or placebo (n = 178) and simultaneously in a 3:3:4 ratio to yoga (n = 107), aerobic exercise (n = 106), or their usual physical activity (n = 142). There were no significant differences in VMS frequency or bother with omega-3s or placebo.¹⁷⁰ Therefore, there is mixed and inconclusive evidence for the use of omega-3s for the management of VMS. (Levels I-II; not recommended)

Vitamin E. Previous studies investigating the effects of vitamin E for VMS treatment included two crossover trials (N = 120; N = 50) that showed limited reduction in VMS frequency with vitamin E compared with placebo.^{171,172} There is very little evidence for vitamin E having significant benefit in reducing VMS. A study from Iran with a total of 93 participants evaluated the use of curcumin alone and vitamin E alone in reducing VMS as well as other symptoms of menopause versus placebo (30 women/group).¹⁷³ There was some improvement seen at 4 weeks for curcumin and at 8 weeks for vitamin E compared with placebo. Results were significant at 4 weeks for curcumin and at 8 weeks for vitamin E, but sample sizes were small, limiting conclusions. Therefore, vitamin E is not recommended for the management of VMS. (Level I; not recommended)

Cannabinoids

The data evaluating the relationship between cannabinoids and menopause symptoms is very limited. This lack of evidence is particularly notable because more than one-quarter of women have used or are using marijuana to treat their menopause symptoms.¹⁷⁴ A systematic review found only three small studies that evaluated cannabis use and its associations with menopause symptoms, including VMS, insomnia, mood, and depression/anxiety.¹⁷⁵ Based on the lack of available evidence, cannabinoids cannot be recommended for the treatment of VMS. (Level II; not recommended)

Key points

- Given mixed evidence of benefit for VMS, soy foods, soy extracts, and the soy metabolite equol are not recommended.
- Given the lack of rigorous, evidence-based scientific research supporting the use of any over-the-counter supplements and herbal therapies for the management of VMS, these remedies are not recommended.
- Cannabinoids are not recommended for the treatment of VMS.

ACUPUNCTURE, OTHER TREATMENTS, AND TECHNOLOGIES

Acupuncture

Acupuncture is a component of the ancient practice of traditional Chinese medicine in which thin needles are inserted into the skin at key points in the body and activated through specific movements (manual acupuncture) or with electrical stimulation (electroacupuncture) to create an energy flow, or *Qi*, which is believed to improve overall health. Sham acupuncture is a placebo-equivalent treatment involving needles inserted at unrelated points or needles that do not pierce the skin.

Over the last decade, several systematic reviews and meta-analyses examined acupuncture versus no treatment or sham intervention for the treatment of VMS. In most systematic

reviews,¹⁷⁶⁻¹⁷⁸ as well as in RCTs,¹⁷⁹ acupuncture was deemed to alleviate some menopause-related symptoms (eg, mood, sleep, pain) as reflected in the reduction in menopause-related total scores (eg, KI, Greene Climacteric Scale) or the improvement in quality-of-life measurements (eg, MSQOL questionnaire); it had, however, little to no clinical benefit for the improvement of VMS compared with sham interventions, either for symptomatic midlife women or for survivors of breast cancer.

Consistent with this conclusion, a 2018 study (umbrella meta-analysis) that included three systematic reviews and four RCTs found modest benefits of acupuncture for the alleviation of menopause-related symptoms, quality of life, and VMS severity or frequency when treatments were compared with no treatment.¹⁸⁰ Results, however, were no longer clinically significant when acupuncture was compared with sham intervention.

There has been a considerable debate regarding the use of appropriate comparisons or control groups in acupuncture studies; some have argued, for example, that sham interventions may not be physiologically inert and therefore would not be the most appropriate comparison for studies or trials that aim to inform clinical practice. It is important to note that although most studies that compared traditional acupuncture with sham interventions found no significant difference in VMS frequency or severity, trials with electroacupuncture showed some benefits with this intervention and even stronger results for electroacupuncture when compared with manual acupuncture.¹⁸¹

In a 2021 model-based meta-analysis, Li and colleagues assessed 17 studies (1,123 participants), including manual acupuncture, electroacupuncture, and sham acupuncture.¹⁷⁸ The authors found that after 8 weeks of treatment, both electroacupuncture and a combination of both acupuncture modalities (traditional acupuncture and electroacupuncture) led to significant reduction of VMS per day compared with sham intervention. Moreover, the benefits of electroacupuncture for VMS were comparable to those reported in previous studies using nonhormone, pharmacologic treatments such as SSRIs, SNRIs, gabapentin, and escitalopram.

Existing evidence does not support the use of traditional acupuncture for the treatment of VMS, neither for midlife women nor for VMS in survivors of breast cancer. (Level I; not recommended). The use of electroacupuncture, although more promising, still warrants further investigation. (Level II; not recommended)

Stellate ganglion block

Stellate ganglion blockade is a widely used treatment for pain management, including for migraine and complex regional pain syndrome. The treatment is accomplished through the injection of an anesthetic agent at the lower cervical or upper thoracic region because the stellate ganglion is located bilaterally in the C6-T2 region of the anterior cervical spine. Adverse events, such as transient seizures or a bleeding complication, are extremely rare and minimized using imaging guidance during the procedure.¹⁸²

Stellate ganglion blockade has emerged as a potential treatment option for VMS in both midlife women and those with breast cancer, although the exact mechanism of action of stellate ganglion blockade on VMS remains unclear.

One randomized, sham-controlled trial assessed active stellate ganglion blockade with bupivacaine versus a sham procedure (subcutaneous saline injection) for VMS in women with natural or surgical menopause (N = 40).¹⁸³ Over a 6-month follow-up, there was a reduction in subjectively reported VMS intensity and frequency (moderate to very severe) in the stellate ganglion blockade group compared with the sham-control group. Moreover, there was a reduction (21%, $P < .05$) of physiologic VMS measured with ambulatory skin conductance monitors from baseline to 3 months in the stellate ganglion blockade group, whereas the sham-control group showed no reduction. Four uncontrolled, open-label studies showed that stellate ganglion blockade reduced VMS, with effects ranging from a 45% to a 90% reduction 6 weeks to several months after blockade.¹⁸⁴⁻¹⁸⁷

In a study of patients with breast cancer (N = 40), stellate ganglion blockade (10 mL 0.5% bupivacaine injected bilaterally) was compared with paroxetine 7.5 mg per day over a 6-week period.¹⁸⁸ Both treatments had a positive effect on an index comprising both VMS frequency and severity, with no significant differences between treatments.

Overall, stellate ganglion blockade might help alleviate moderate to very severe VMS in select women. Results from ongoing larger RCTs are needed to provide more definitive evidence. Given that stellate ganglion blockade is a procedure that involves potential risks and AEs, its potential use for VMS should be carefully evaluated. (Levels II-III; recommended)

Calibration of neural oscillations

High-resolution, relational, resonance-based electroencephalic mirroring is a closed-loop acoustic stimulation neurotechnology based on the principle of allostasis. Essentially, scalp sensors and software algorithms translate specific brain frequencies into audible tones of varying pitch in real time, and these tones are immediately mirrored back via ear buds, allowing the brain to “listen to itself” in an acoustic mirror. High-resolution, relational, resonance-based electroencephalic mirroring has shown some preliminary benefits for the management of insomnia¹⁸⁹ and for military-related stress.¹⁹⁰

In an uncontrolled study, 14 women showed a significant reduction in VMS frequency and severity after administration with high-resolution, relational, resonance-based electroencephalic mirroring aimed at autocalibration of neural oscillations.¹⁹¹ Given the lack of controlled trials, high-resolution, relational, resonance-based electroencephalic mirroring is not recommended for treatment of VMS. (Level II; not recommended)

Chiropractic intervention

There have been no clinical trials of chiropractic interventions for VMS, and epidemiologic survey data show no association between use of such interventions and VMS.¹⁹² Chiropractic interventions are not recommended for treatment of VMS. (Level II; not recommended)

Key points

- Existing evidence does not support the use of traditional acupuncture for the treatment of VMS; electroacupuncture requires more rigorous study before it can be recommended.

- Stellate ganglion blockade might alleviate moderate to very severe VMS in select women but is associated with potential risk.
- Calibration of neural oscillations and chiropractic interventions are not recommended for treatment of VMS.

RECOMMENDATIONS

Vasomotor symptoms are common in midlife women and remain undertreated. These symptoms can disrupt a women’s overall quality of life and last a mean duration of 7 to 9 years, longer in some women. Hormone therapy remains the first-line recommended treatment to ameliorate VMS in healthy women at or around the time of menopause. However, it is important to recognize that not all women are candidates for HT because of contraindications or personal preference. This Position Statement supports the use of and recommends CBT, clinical hypnosis, SSRIs, SNRIs, gabapentin, fezolinetant (Level I); oxybutynin (Levels I-II); weight loss, stellate ganglion block (Levels II-III). There is negative or insufficient evidence for these, so they are not recommended: paced respiration (Level I); supplements/herbal remedies (Levels I-II); cooling techniques, avoiding triggers, exercise, yoga, MBI, relaxation, suvorexant, soy foods and soy extracts, soy metabolite equol, cannabinoids, acupuncture, calibration of neural oscillations (Level II), chiropractic interventions, clonidine; (Levels I-III); dietary modification and pregabalin (Level III). Clinicians should be knowledgeable of the nonhormone options supported by evidence that are available to offer to women (Table 2).

ACKNOWLEDGMENTS AND DISCLOSURES

NAMS appreciates the contributions of the Advisory Panel and the work of the NAMS Board of Trustees on this Position Statement. The authors, planners, reviewers, and staff who were in a position to control and influence the content of this activity were required to disclose all financial relationships with any ineligible company within the last 24 months. Any financial relationships that were determined by NAMS to be relevant to the activity have been mitigated.

Acknowledgments

The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society Advisory Panel: *Lead*, Chrisandra L. Shufelt, MD, MS, FACP, NCMP, Professor and Chair, Division of General Internal Medicine, Associate Director, Women’s Health Research, Mayo Clinic, Jacksonville, Florida. Vivien Brown, MDCM, CCFP, FCFP, NCMP, Assistant Professor, Faculty of Medicine, Department of Family and Community Medicine, University of Toronto, Ontario, Canada. Janet S. Carpenter, PhD, RN, FAAN, Distinguished Professor, Audrey Geisel Endowed Chair in Innovation, Indiana University School of Nursing, Indianapolis, Indiana. Lisa Astalos Chism, DNP, APRN, BC, CSC, NCMP, FAAN, FAANP, Clinical Director, Oakland Macomb Ob Gyn Center for Breast Health, Rochester Hills, Michigan. Stephanie S. Faubion, MD, MBA, FACP, NCMP, IF, Professor and Chair, Department of Medicine, Mayo Clinic, Jacksonville, Florida; Penny and Bill George Director, Mayo Clinic Center for Women’s Health. Hadine Joffe, MD, MSc,

TABLE 2. Treatment recommendations for nonhormone therapies for vasomotor symptoms with levels of evidence

Category	Treatment	Recommended	Not recommended
Lifestyle	Cooling techniques		Level II
	Avoiding triggers		Level II
	Exercise		Level II
	Yoga		Level II
	Dietary modifications		Level III
	Weight loss	Levels II-III	
Mind-body techniques	Cognitive-behavioral therapy	Level I	
	Mindfulness-based interventions		Level II
	Clinical hypnosis	Level I	
	Paced respiration		Level I
	Relaxation		Level II
Prescription therapies	SSRIs/SNRIs	Level I	
	Gabapentin	Level I	
	Pregabalin		Level III
	Clonidine		Levels I-III
	Oxybutynin	Levels I-II	
	Suvorexant		Level II
	Fezolinetant	Level I	
Dietary supplements	Soy foods and soy extracts		Level II
	Soy metabolites equol		Level II
	Supplements/Herbal remedies ^a		Levels I-III
	Cannabinoids		Level II
Acupuncture, other treatments, and technologies	Acupuncture		Level II
	Stellate ganglion block	Levels II-III	
	Calibration of neural oscillations		Level II
	Chiropractic intervention		Level II

Level I, good and consistent scientific evidence; Level II, limited or inconsistent scientific evidence; Level III, consensus and expert opinion.

SNRIs, serotonin-norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors.

^aPollen extract, ammonium succinate, *Lactobacillus acidophilus*, rhubarb, black cohosh, wild yam, dong quai, evening primrose oil, maca, ginseng, *labisia pumila/eurycoma longifolia*, chasteberry, milk thistle, omega-3 fatty acids, vitamin E.

Executive Director, Mary Horrigan Connors Center for Women’s Health and Gender Biology; Paula A. Johnson Professor of Psychiatry in the Field of Women’s Health; Executive Vice Chair for Academic and Faculty Affairs, Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts. Juliana M. Kling, MD, MPH, NCMP, FACP, IF, Professor of Medicine; Chair, Women’s Health Internal Medicine; Associate Chair of Equity, Inclusion, and Diversity, Department of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona. Claudio N. Soares, MD, PhD, FRCPC, MBA, Professor and Head, Department of Psychiatry; Chair, Psychedelic Science Advisory Committee, Queen’s University School of Medicine; Executive Lead, Canadian Biomarker Integration Network in Depression (CAN-BIND); President and Chief Executive Officer, CAN-BIND Solutions, Ontario, Canada. Rebecca C. Thurston, PhD, FABMR, Pittsburgh Foundation

Chair in Women’s Health and Dementia; Professor of Psychiatry, Psychology, Epidemiology and Clinical and Translational Science; Director, Women’s Biobehavioral Health Research Program; Director, Cardiovascular Behavioral Medicine Research Training Program, University of Pittsburgh, Pittsburgh, Pennsylvania.

NAMS recognizes the contributions of Carolyn Develen, NAMS Chief Operating Officer, and Kathy Method, MA, NAMS Editor.

This position statement was reviewed and approved by the 2022-2023 NAMS Board of Trustees: *President*, Susan D. Reed, MD, MPH, MS, NCMP, Professor Emeritus, Department of Obstetrics and Gynecology; Adjunct Professor of Epidemiology, University of Washington School of Medicine, Seattle, Washington. *President-Elect*, Lisa C. Larkin, MD, FACP, NCMP, IF, Founder and Chief Executive Officer, Ms.Medicine, Cincinnati, Ohio. *Secretary*, Monica M. Christmas, MD, FACOG, NCMP, Associate Professor and Director of the Menopause Program and Center for Women’s Integrated Health, Section of Minimally Invasive Gynecologic Surgery, UChicago Medicine and Biological Sciences, Chicago, Illinois. *Treasurer*, Claudio N. Soares, MD, PhD, FRCPC, MBA, Professor and Head, Department of Psychiatry; Chair, Psychedelic Science Advisory Committee, Queen’s University School of Medicine; Executive Lead, Canadian Biomarker Integration Network in Depression (CAN-BIND); President and Chief Executive Officer, CAN-BIND Solutions, Ontario, Canada. *Medical Director*, Stephanie S. Faubion, MD, MBA, FACP, NCMP, IF, Professor and Chair, Department of Medicine, Mayo Clinic, Jacksonville, Florida; Penny and Bill George Director, Mayo Clinic Center for Women’s Health. *Immediate Past-President*, Chrisandra L. Shufelt, MD, MS, FACP, NCMP, Professor and Chair, Division of General Internal Medicine, Associate Director, Women’s Health Research Center, Mayo Clinic, Jacksonville, Florida. Janet S. Carpenter, PhD, RN, FAAN, Distinguished Professor, Audrey Geisel Endowed Chair in Innovation, Indiana University School of Nursing, Indianapolis, Indiana. Samar R. El Khoudary, PhD, MPH, BPharm, FAHA, Associate Professor, Department of Epidemiology, Epidemiology Data Center, University of Pittsburgh, Pittsburgh, Pennsylvania. Laurie S. Jeffers, DNP, FNP-BC, NCMP, Codirector, Center for Midlife Health and Menopause, NYU Grossman School of Medicine, Department of Obstetrics and Gynecology, NYU Langone Health, New York, New York. Hadine Joffe, MD, MSc, Executive Director, Mary Horrigan Connors Center for Women’s Health and Gender Biology; Paula A. Johnson Professor of Psychiatry in the Field of Women’s Health; Executive Vice Chair for Academic and Faculty Affairs, Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts. Cheryl Cox Kinney, MD, FACOG, NCMP, Director, Center for Female Health and Hormone Disorders, Medical City Dallas, Dallas, Texas. Isaac Schiff, CM, MD, Editor-in-Chief, *Menopause*, Joe Vincent Meigs Distinguished Professor of Gynecology, Harvard Medical School; Chief, Department of Obstetrics and Gynecology, Emeritus, The Women’s Care Division, Massachusetts General Hospital, Boston, Massachusetts. Wen Shen, MD, MPH, Associate Professor of Gynecologic Specialties; Associate

Professor of Oncology Center; Associate Professor, Johns Hopkins School of Nursing Joint Appointment; Codirector of Johns Hopkins Women's Wellness and Healthy Aging Program, Johns Hopkins University School of Medicine, Baltimore, Maryland. Holly N. Thomas, MD, MS, NCMP, Assistant Professor of Medicine and Clinical and Translational Research, Director of the Comparative Effectiveness Research Track, Director of the Leadership and Discovery Program, University of Pittsburgh, Pittsburgh, Pennsylvania.

Financial disclosures

All financial relationships with ineligible companies have been mitigated. For the Advisory Panel: Dr. Faubion reports no financial relationships with ineligible companies. Dr. Brown reports Consultant/Advisory Board and Speakers' Bureau for GSK, Merck, Pfizer, Sanofi, Eisai, Sequeris, and Moderna; Speakers' Bureau for Abbvie. Dr. Carpenter reports Consultant/Advisory Board for the University of Wisconsin Milwaukee, Simumetirx, SMX Health; Grant/Research Support from the NIH; Royalties/Patents from Mapi Trust; Owner of JSCarpenter LLC. Dr. Chism reports Consultant/Advisory Board for Astellas and Pharmavite; Royalties from Jones and Bartlett Learning. Dr. Joffe reports Consultant/Advisory Board for Bayer, Hello Therapeutics, and Merck; Grant/Research Support from Merck, the NIH, and Pfizer. Dr. Kling reports Consultant for Kindra/Procter & Gamble and Triangle Insights Group; Speaker for Pri Med and SNSMA. Dr. Soares reports Consultant/Advisory Board for Bayer, Diamond Therapeutics, Eisai, Otsuka, and Pfizer; Executive Committee Member for the Canadian Biomarker Integration Network in Depression. Dr. Shufelt reports Grant/Research Support from the NIH. Dr. Thurston reports Consultant for Astellas Pharma, Happify Health, Pfizer, Vira Health, and Virtue Health.

For additional contributors: Ms. Develen and Ms. Method report no financial relationships with ineligible companies.

For the NAMS Board of Trustees members who were not members of the Advisory Panel: Dr. Jeffers, Dr. Kinney, and Dr. Schiff report no financial relationships with ineligible companies. Dr. Christmas reports Consultant/Advisory Board for the FDA Obstetrics, Reproductive, and Urologic Drugs Advisory Committee. Dr. El Khoudary reports Grant/Research Support from the NIH. Dr. Larkin reports Consultant/Advisory Board for Astellas, Myovant/Pfizer, Pharmavite, Procter & Gamble, Solv Wellness, and TherapeuticsMD; Speakers' Bureau for Abbvie; and Board Member for HealthyWomen. Dr. Reed reports Consultant/Advisory Board for the NIH; Grant/Research Support for Bayer and the NIH; and Royalties/Patents for *UpToDate*. Dr. Shen reports Consultant/Advisory Board for Merck; Stock/Ownership for Astra Zeneca, Akzo Nobel, Bristol Myers Squibb, Hologic, Johnson & Johnson, and Merck. Dr. Thomas reports Consultant/Advisory Board for Astellas; Grant/Research Support from the NIH.

References

- Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health Across the Nation. *Am J Public Health* 2006;96:1226-1235. doi: 10.2105/AJPH.2005.066936
- Avis NE, Crawford SL, Greendale G, et al. Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. *JAMA. Intern Med* 2015;175:531-539. doi: 10.1001/jamainternmed.2014.8063
- Etinger B, Wang SM, Leslie RS, et al. Evolution of postmenopausal hormone therapy between 2002 and 2009. *Menopause* 2012;19:610-615. doi: 10.1097/gme.0b013e31823a3e5d
- Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative. *Menopause* 2012;19:616-621. doi: 10.1097/gme.0b013e31824bb039
- Weissfeld JL, Liu W, Woods C, et al. Trends in oral and vaginally administered estrogen use among US women 50 years of age and older with commercial health insurance. *Menopause* 2018;25:611-614. doi: 10.1097/GME.0000000000001054
- Crawford SL, Crandall CJ, Derby CA, et al. Menopausal hormone therapy trends before versus after 2002: impact of the Women's Health Initiative study results. *Menopause* 2018;26:588-597. doi: 10.1097/GME.0000000000001282
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. *Menopause* 2022;:767-794. doi: 10.1097/GME.0000000000002028
- van Die MD, Teede HJ, Bone KM, Reece JE, Burger HG. Predictors of placebo response in a randomized, controlled trial of phytotherapy in menopause. *Menopause* 2009;16:792-796. doi: 10.1097/GME.0b013e318199d5e6
- Freedman RR, Norton D, Woodward S, Cornélissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. *J Clin Endocrinol Metab* 1995;80:2354-2358. doi: 10.1210/jcem.80.8.7629229
- Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. *Am J Obstet Gynecol* 1999;181:66-70. doi: 10.1016/s0002-9378(99)70437-0
- Freedman RR, Woodward S. Core body temperature during menopausal hot flashes. *Fertil Steril* 1996;65:1141-1144.
- Baker FC, de Zambotti M, Chiappetta L, Nofzinger EA. Effects of forehead cooling and supportive care on menopause-related sleep difficulties, hot flashes and menopausal symptoms: a pilot study. *Behav Sleep Med* 2021;19:615-628. doi: 10.1080/15402002.2020.1826484
- Composto J, Leichman ES, Luedtke K, Mindell JA. Thermal comfort intervention for hot-flash related insomnia symptoms in perimenopausal and postmenopausal-aged women: an exploratory study. *Behav Sleep Med* 2021;19:38-47. doi: 10.1080/15402002.2019.1699100
- Zhang L, Ruan X, Cui Y, Gu M, Mueck AO. Menopausal symptoms and associated social and environmental factors in midlife Chinese women. *Clin Interv Aging* 2020;15:2195-2208. doi: 10.2147/CIA.S278976
- Guthrie JR, Dennerstein L, Hopper JL, Burger HG. Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women. *Obstet Gynecol* 1996;88:437-442. doi: 10.1016/0029-7844(96)00196-2
- Ivarsson T, Spetz AC, Hammar M. Physical exercise and vasomotor symptoms in postmenopausal women. *Maturitas* 1998;29:139-146. doi: 10.1016/s0378-5122(98)00004-8
- Hammar M, Berg G, Lindgren R. Does physical exercise influence the frequency of postmenopausal hot flushes? *Acta Obstet Gynecol Scand* 1990;69:409-412. doi: 10.3109/00016349009013303
- Haimov-Kochman R, Constatini N, Brzezinski A, Hochner-Celnikier D. Regular exercise is the most significant lifestyle parameter associated with the severity of climacteric symptoms: a cross sectional study. *Eur J Obstet Gynecol Reprod Biol* 2013;170:229-234. doi: 10.1016/j.ejogrb.2013.06.018
- Kim MJ, Cho J, Ahn Y, Yim G, Park HY. Association between physical activity and menopausal symptoms in perimenopausal women. *BMC Womens Health* 2014;14:122. doi: 10.1186/1472-6874-14-122
- Daley A, MacArthur C, Mutrie N, Stokes-Lampard H. Exercise for vasomotor menopausal symptoms. *Cochrane Database Syst Rev* 2007; CD006108. doi: 10.1002/14651858.CD006108.pub2
- Daley A, Stokes-Lampard H, Macarthur C. Exercise for vasomotor menopausal symptoms. *Cochrane Database Syst Rev* 2011;CD006108. doi: 10.1002/14651858.CD006108.pub3
- Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. *Cochrane Database Syst Rev* 2014; CD006108. doi: 10.1002/14651858.CD006108.pub4
- Elavsky S, McAuley E. Physical activity and mental health outcomes during menopause: a randomized controlled trial. *Ann Behav Med* 2007;33:132-142. doi: 10.1007/BF02879894

24. Sternfeld B, Guthrie KA, Ensrud KE, et al. Efficacy of exercise for menopausal symptoms: a randomized controlled trial. *Menopause* 2014; 21:330-338. doi: 10.1097/GME.0b013e31829e4089
25. Diem SJ, LaCroix AZ, Reed SD, et al. Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials. *Menopause* 2020;27:1126-1136. doi: 10.1097/GME.0000000000001597
26. Cramer H, Peng W, Lauche R. Yoga for menopausal symptoms—a systematic review and meta-analysis. *Maturitas* 2018;109:13-25. doi: 10.1016/j.maturitas.2017.12.005
27. Barnard N, Kahleova H, Holtz DN, et al. A dietary intervention for vasomotor symptoms of menopause: a randomized, controlled trial. *Menopause* 2023;30:80-87. doi: 10.1097/GME.0000000000002080
28. Soleymani M, Siassi F, Qorbani M, et al. Dietary patterns and their association with menopausal symptoms: a cross-sectional study. *Menopause* 2019;26:365-372. doi: 10.1097/GME.0000000000001245
29. Beezhold B, Radnitz C, McGrath RE, Feldman A. Vegans report less bothersome vasomotor and physical menopausal symptoms than omnivores. *Maturitas* 2018;112:12-17. doi: 10.1016/j.maturitas.2018.03.009
30. Herber-Gast GC, Mishra GD. Fruit, Mediterranean-style, and high-fat and -sugar diets are associated with the risk of night sweats and hot flashes in midlife: results from a prospective cohort study. *Am J Clin Nutr* 2013;97:1092-1099. doi: 10.3945/ajcn.112.049965
31. Flor-Alemayn M, Marín-Jiménez N, Coll-Risco I, Aranda P, Aparicio VA. Influence of dietary habits and Mediterranean diet adherence on menopausal symptoms. The FLAMENCO project. *Menopause* 2020;27:1015-1021. doi: 10.1097/GME.0000000000001574
32. Thurston RC, Sowers MR, Sternfeld B, et al. Gains in body fat and vasomotor symptom reporting over the menopausal transition: the Study of Women's Health Across the Nation. *Am J Epidemiol* 2009;170:766-774. doi: 10.1093/aje/kwp203
33. Thurston RC, Ewing LJ, Low CA, Christie AJ, Levine MD. Behavioral weight loss for the management of menopausal hot flashes: a pilot study. *Menopause* 2015;22:59-65. doi: 10.1097/GME.0000000000000274
34. Huang AJ, Subak LL, Wing R, et al; Program to Reduce Incontinence by Diet and Exercise Investigators. An intensive behavioral weight loss intervention and hot flashes in women. *Arch Intern Med* 2010;170:1161-1167. doi: 10.1001/archinternmed.2010.162. Erratum in *Arch Intern Med* 2010;170:1601.
35. Anderson DJ, Chung HF, Seib CA, et al. Obesity, smoking, and risk of vasomotor menopausal symptoms: a pooled analysis of eight cohort studies. *Am J Obstet Gynecol* 2020;222:478.e1-478.e17. doi: 10.1016/j.ajog.2019.10.103
36. Thurston RC, Santoro N, Matthews KA. Adiposity and hot flashes in midlife women: a modifying role of age. *J Clin Endocrinol Metab* 2011; 96:E1588-E1595. doi: 10.1210/jc.2011-1082
37. Kapoor E, Faubion S, Hurt RT, et al. A selective serotonin receptor agonist for weight loss and management of menopausal vasomotor symptoms in overweight midlife women: a pilot study. *Menopause* 2020;27:1228-1235. doi: 10.1097/GME.0000000000001599
38. Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. *Lancet Oncol* 2012;13:309-318. doi: 10.1016/S1470-2045(11)70364-3
39. Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flashes and night sweats (MENOS 2): a randomized controlled trial. *Menopause* 2012;19:749-759. doi: 10.1097/gme.0b013e31823fe835
40. Norton S, Chilcot J, Hunter MS. Cognitive-behavior therapy for menopausal symptoms (hot flashes and night sweats): moderators and mediators of treatment effects. *Menopause* 2014;21:574-578. doi: 10.1097/GME.0000000000000095
41. Fenlon D, Maishman T, Day L, et al. Effectiveness of nurse-led group CBT for hot flashes and night sweats in women with breast cancer: results of the MENOS4 randomised controlled trial. *Psychooncology* 2020;29:1514-1523. doi: 10.1002/pon.5432
42. Atema V, van Leeuwen M, Kieffer JM, et al. Efficacy of internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. *J Clin Oncol* 2019;37:809-822. doi: 10.1200/JCO.18.00655
43. Hardy C, Griffiths A, Norton S, Hunter MS. Self-help cognitive behavior therapy for working women with problematic hot flashes and night sweats (MENOS@Work): a multicenter randomized controlled trial. *Menopause* 2018;508-519. doi: 10.1097/GME.0000000000001048
44. Duijts SFA, van Beurden M, Oldenburg HAS, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. *J Clin Oncol* 2012;30:4124-4133. doi: 10.1200/JCO.2012.41.8525
45. Green SM, Donegan E, Frey BN, et al. Cognitive behavior therapy for menopausal symptoms (CBT-Meno): a randomized controlled trial. *Menopause* 2019;26:972-980. doi: 10.1097/GME.0000000000001363
46. Carmody JF, Crawford S, Salmoirago-Blotcher E, Leung K, Churchill L, Olenzki N. Mindfulness training for coping with hot flashes: results of a randomized trial. *Menopause* 2011;18:611-620. doi: 10.1097/gme.0b013e318204a05c
47. Wong C, Yip BHK, Gao T, et al. Mindfulness-based stress reduction (MBSR) or psychoeducation for the reduction of menopausal symptoms: a randomized, controlled clinical trial. *Sci Rep* 2018;8:6609. doi: 10.1038/s41598-018-24945-4
48. Yazdani Aliabadi M, Javadnoori M, Saki Malehi A, Aslani K. A study of mindfulness-based stress-reduction training effects on menopause-specific quality of life in postmenopausal women: a randomized controlled trial. *Complement Ther Clin Pract* 2021;44:101398. doi: 10.1016/j.ctcp.2021.101398
49. Bower JE, Crosswell AD, Stanton AL, et al. Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. *Cancer* 2015;121:1240-1240. Erratum in: *Cancer* 2015;121:1910. doi: 10.1002/cncr.29194
50. van Driel C, de Bock GH, Schroevers MJ, Mourits MJ. Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial. *BJOG*. 2019;126:402-411. doi: 10.1111/1471-0528.15471
51. Chen TL, Chang SC, Huang CY, Wang HH. Effectiveness of mindfulness-based interventions on quality of life and menopausal symptoms in menopausal women: a meta-analysis. *J Psychosom Res* 2021;147:110515. doi: 10.1016/j.jpsychores.2021.110515
52. Elkins G, Marcus J, Stearns V, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. *J Clin Oncol* 2008;26:5022-5026. doi: 10.1200/JCO.2008.16.6389
53. Elkins GR, Fisher WI, Johnson AK, Carpenter JS, Keith TZ. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. *Menopause* 2013;20:291-298. doi: 10.1097/gme.0b013e31826ce3ed
54. Sliwinski JR, Elkins GR. Hypnotherapy to reduce hot flashes: examination of response expectancies as a mediator of outcomes. *J Evid Based Complement Altern Med* 2017;22:652-659. doi: 10.1177/2156587217708523
55. Germaine LM, Freedman RR. Behavioral treatment of menopausal hot flashes: evaluation by objective methods. *J Consult Clin Psychol* 1984; 52:1072-1079. doi: 10.1037//0022-006x.52.6.1072
56. Freedman RR, Woodward S. Behavioral treatment of menopausal hot flashes: evaluation by ambulatory monitoring. *Am J Obstet Gynecol* 1992; 167:436-439. doi: 10.1016/s0002-9378(11)91425-2
57. Freedman RR, Woodward S, Brown B, Javaid JL, Pandey GN. Biochemical and thermoregulatory effects of behavioral treatment for menopausal hot flashes. *Menopause* 1995;2:211-218.
58. Carpenter JS, Burns DS, Wu J, et al. Paced respiration for vasomotor and other menopausal symptoms: a randomized, controlled trial. *J Gen Intern Med* 2013;28:193-200. doi: 10.1007/s11606-012-2202-6
59. Sood R, Sood A, Wolf SL, et al. Paced breathing compared with usual breathing for hot flashes. *Menopause* 2013;20:179-184. doi: 10.1097/gme.0b013e31826934b6
60. Huang AJ, Phillips S, Schembri M, Vittinghoff E, Grady D. Device-guided slow-paced respiration for menopausal hot flashes: a randomized controlled trial. *Obstet Gynecol* 2015;125:1130-1138. doi: 10.1097/AOG.0000000000000821
61. Saensak S, Vutyavanich T, Somboonporn W, Srisurapanont M. Relaxation for perimenopausal and postmenopausal symptoms. *Cochrane Database Syst Rev* 2014;7:CD008582. doi: 10.1002/14651858.CD008582.pub2
62. Tremblay A, Sheeran L, Aranda SK. Psychoeducational interventions to alleviate hot flashes: a systematic review. *Menopause* 2008;15:193-202. doi: 10.1097/gme.0b013e31805c08dc
63. Lindh-Åstrand L, Nedstrand E. Effects of applied relaxation on VMS in postmenopausal women: a randomized controlled trial. *Menopause* 2013; 20:401-408. doi: 10.1097/gme.0b013e318272ce80
64. Lindh-Åstrand L, Holm ACS, Sydsjö G, Andersson G, Carlbring P, Nedstrand E. Internet-delivered applied relaxation for vasomotor symptoms in postmenopausal women: lessons from a failed trial. *Maturitas* 2015;80: 432-434. doi: 10.1016/j.maturitas.2015.01.010

65. Irvin JH, Domar AD, Clark C, Zuttermeister PC, Friedman R. The effects of relaxation response training on menopausal symptoms. *J Psychosom Obstet Gynaecol* 1996;17:202-207. doi: 10.3109/01674829609025684
66. Nedstrand E, Wijma K, Wyon Y, Hammar M. Vasomotor symptoms decrease in women with breast cancer randomized to treatment with applied relaxation or electro-acupuncture: a preliminary study. *Climacteric* 2005;8:243-250. doi: 10.1080/13697130500118050
67. Nedstrand E, Wijma K, Wyon Y, Hammar M. Applied relaxation and oral estradiol treatment of VMS in postmenopausal women. *Maturitas* 2005;51:154-162. doi: 10.1016/j.maturitas.2004.05.017
68. Fenlon DR, Corner JL, Haviland JS. A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer. *J Pain Symptom Manage* 2008;35:397-405. doi: 10.1016/j.jpainsymman.2007.05.014
69. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. *JAMA* 2006;295:2057-2071. doi: 10.1001/jama.295.17.2057
70. Shams T, Firwana B, Habib F, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. *J Gen Intern Med* 2014;29:204-213. doi: 10.1007/s11606-013-2535-9
71. Sun Z, Hao Y, Zhang M. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. *Gynecol Obstet Invest* 2013;75:255-262. doi: 10.1159/000348564
72. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. *J Clin Oncol* 2009;27:2831-2837. doi: 10.1200/JCO.2008.19.6253
73. Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot flashes in women with a history of breast cancer. *Cochrane Database Syst Rev* 2010;CD004923. doi: 10.1002/14651858.CD004923.pub2
74. Fisher WI, Johnson AK, Elkins GR, et al. Risk factors, pathophysiology, and treatment of hot flashes in cancer. *CA Cancer J Clin* 2013;63:167-192. doi: 10.3322/caac.21171
75. Wei D, Chen Y, Wu C, et al. Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta-analysis. *BJOG* 2016;123:1735-1743. doi: 10.1111/1471-0528.13951
76. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. *JAMA* 2011;305:267-274. doi: 10.1001/jama.2010.2016
77. Davari-Tanha F, Soleymani-Farsani M, Asadi M, Shariat M, Shirazi M, Hadizadeh H. Comparison of citalopram and venlafaxine's role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial. *Arch Gynecol Obstet* 2016;293:1007-1013. doi: 10.1007/s00404-015-3900-1
78. Ramaswami R, Villarreal MD, Pitta DM, Carpenter JS, Stebbing J, Kalesan B. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. *Breast Cancer Res Treat* 2015;152:231-237. doi: 10.1007/s10549-015-3465-5
79. Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. *JAMA Intern Med* 2014;174:1058-1066. doi: 10.1001/jamainternmed.2014.1891
80. Sun Z, Hao Y, Zhang M. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. *Gynecol Obstet Invest* 2013;75:255-262. doi: 10.1159/000348564
81. Biglia N, Bounous VE, Susini T, et al. Duloxetine and escitalopram for hot flashes: efficacy and compliance in breast cancer survivors. *Eur J Cancer Care* 2018;27. doi: 10.1111/ecc.12484
82. Freeman MP, Hirschberg AM, Wang B, et al. Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition. *Maturitas* 2013;75:170-174. doi: 10.1016/j.maturitas.2013.03.007
83. Grady D, Cohen B, Tice J, Kristof M, Olyae A, Sawaya GF. Ineffectiveness of sertraline for treatment of menopausal hot flashes: a randomized controlled trial. *Obstet Gynecol* 2007;109:823-830. doi: 10.1097/01.AOG.0000258278.73505.fa
84. Kerwin JP, Gordon PR, Senf JH. The variable response of women with menopausal hot flashes when treated with sertraline. *Menopause* 2007;14:841-845. doi: 10.1097/GME.0b013e31802e7f22
85. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. *J Clin Oncol* 2002;20:1578-1583. doi: 10.1200/JCO.2002.20.6.1578
86. Kalay AE, Demir B, Haberal A, Kalay M, Kandemir O. Efficacy of citalopram on climacteric symptoms. *Menopause* 2007;14:223-229. doi: 10.1097/01.gme.0000243571.55699.4a
87. Guthrie KA, LaCroix AZ, Ensrud KE, et al. Pooled analysis of six pharmacologic and nonpharmacologic interventions for vasomotor symptoms. *Obstet Gynecol* 2015;126:413-422. doi: 10.1097/AOG.0000000000000927
88. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flashes. *Cochrane Database Syst Rev* 2004;2004:CD002978. doi: 10.1002/14651858.CD002978.pub2
89. Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. *Menopause* 2013;20:1027-1035. doi: 10.1097/GME.0b013e3182a66aa7
90. Riemma G, Schiattarella A, La Verde M, et al. Efficacy of low-dose paroxetine for the treatment of hot flashes in surgical and physiological postmenopausal women: systematic review and meta-analysis of randomized trials. *Medicina (Kaunas)* 2019;55:554. doi: 10.3390/medicina55090554
91. Hanay EM, Warden SJ, Bliizotes MM. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? *Bone* 2010;46:13-17. doi: 10.1016/j.bone.2009.07.083
92. Sheu YH, Lanteigne A, Stürmer T, Pate V, Azrael D, Miller M. SSRI use and risk of fractures among perimenopausal women without mental disorders. *Inj Prev* 2015;21:397-403. doi: 10.1136/injuryprev-2014-041483
93. Diem SJ, Joffe H, Larson JC, et al. Effects of escitalopram on markers of bone turnover: a randomized clinical trial. *J Clin Endocrinol Metab* 2014;99:E1732-E1737. doi: 10.1210/jc.2014-2288
94. Brown JN, Wright BR. Use of gabapentin in patients experiencing hot flashes. *Pharmacotherapy* 2009;29:74-81. doi: 10.1592/phco.29.1.74
95. Hayes LP, Carroll DG, Kelley KW. Use of gabapentin for the management of natural or surgical menopausal hot flashes. *Ann Pharmacother* 2011;45:388-394. doi: 10.1345/aph.1P366
96. Yoon SH, Lee JY, Lee C, Lee H, Kim SN. Gabapentin for the treatment of hot flashes in menopause: a meta-analysis. *Menopause* 2020;27:485-493. doi: 10.1097/GME.00000000000001491
97. Reddy SY, Warner H, Guttuso T Jr., et al. Gabapentin, estrogen, and placebo for treating hot flashes: a randomized controlled trial. *Obstet Gynecol* 2006;108:41-48. doi: 10.1097/01.AOG.0000222383.43913.ed
98. Loprinzi CL, Qin R, Balcueva EP, et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. *J Clin Oncol* 2010;28:641-647. Erratum in: *J Clin Oncol* 2010;28:1808. doi: 10.1200/JCO.2009.24.5647
99. Kim WO, Kil HK, Yoon KB, Yoo JH. Treatment of generalized hyperhidrosis with oxybutynin in postmenopausal patients. *Acta Derm Venereol* 2010;90:291-293. doi: 10.2340/00015555-0828
100. Simon JA, Gaines T, LaGuardia KD; Extended-Release Oxybutynin Therapy for VMS Study Group. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. *Menopause* 2016;23:1214-1221. doi: 10.1097/GME.0000000000000773
101. Leon-Ferre RA, Novotny PJ, Wolfe EG, et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603). *JNCI Cancer Spectr* 2019;21:pkz088. doi: 10.1093/jncics/pkz088
102. Duong V, Iwamoto A, Pennycuff J, Kudish B, Iglesia C. A systematic review of neurocognitive dysfunction with overactive bladder medications. *Int Urogynecol J* 2021;32:2693-2702. doi: 10.1007/s00192-021-04909-5
103. Risacher SL, McDonald BC, Tallman EF, et al; Alzheimer's Disease Neuroimaging Initiative. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. *JAMA Neurol* 2016;73:721-732. doi: 10.1001/jamaneurol.2016.0580
104. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. *JAMA Intern Med* 2015;175:401-407. doi: 10.1001/jamainternmed.2014.7663
105. El-Sedeek MS, Korish AA, Deef MM. Plasma orexin-A levels in postmenopausal women: possible interaction with estrogen and correlation with cardiovascular risk status. *BJOG* 2010;117:488-492. doi: 10.1111/j.1471-0528.2009.02474.x
106. Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. *Biol Psychiatry* 2016;79:136-148. doi: 10.1016/j.biopsych.2014.10.003
107. Herring WJ, Connor KM, Snyder E, et al. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data. *Sleep Med* 2019;56:219-223. doi: 10.1016/j.sleep.2018.09.010

108. Herring WJ, Connor KM, Snyder E, et al. Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials. *J Clin Sleep Med* 2016;12:1215-1225. doi: 10.5664/jcsm.6116
109. Rahman SA, Nathan MD, Wiley A, et al. A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia in midlife women. *Sleep* 2022;45:zsac007. doi: 10.1093/sleep/zsac00
110. Goodman RL, Herbison AE, Lehman MN, Navarro VM. Neuroendocrine control of gonadotropin-releasing hormone: pulsatile and surge modes of secretion. *J Neuroendocrinol* 2022;18:e13094. doi: 10.1111/jne.13094
111. Rance NE, Young WS 3rd. Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalamus of postmenopausal women. *Endocrinology* 1991;128:2239-2247. doi: 10.1210/endo-128-5-2239
112. Padilla SL, Johnson CW, Barker FD, Patterson MA, Palmiter RD. A neural circuit underlying the generation of hot flashes. *Cell Rep* 2018;24:271-277. doi: 10.1016/j.celrep.2018.06.037
113. McCarthy EA, Dischino D, Maguire C, et al. Inhibiting kiss1 neurons with kappa opioid receptor agonists to treat polycystic ovary syndrome and vasomotor symptoms. *J Clin Endocrinol Metab* 2022;107:e328-e347. doi: 10.1210/clinem/dgab602
114. Depypere H, Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. *J Clin Endocrinol Metab* 2019;104:5893-5905. doi: 10.1210/jc.2019-00677
115. Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. *Menopause* 2020;27:382-392. doi: 10.1097/GME.00000000000001510
116. Simon JA, Anderson RA, Ballantyne E, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). *Menopause* 2023;30:239-246. doi: 10.1097/GME.0000000000002138
117. Prague JK, Roberts RE, Comminos AN, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flashes: a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet* 2017;389:1809-1820. doi: 10.1016/S0140-6736(17)30823-1
118. Prague JK, Roberts RE, Comminos AN, et al. Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action. *Menopause* 2018;25:862-869. doi: 10.1097/GME.0000000000001090
119. Johnson KA, Martin N, Nappi RE, et al. Efficacy and safety of fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause: a phase 3 RCT. *J Clin Endocrinol Metab* 2023;3:dgad058. doi: 10.1210/clinem/dgad058
120. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. *Lancet* 2023;401:1091-1102. doi: 10.1016/S0140-6736(23)00085-5
121. Trower M, Anderson RA, Ballantyne E, Joffe H, Kerr M, Pawsey S. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. *Menopause* 2020;27:498-505. doi: 10.1097/GME.0000000000001500
122. Santoro N, Waldbaum A, Lederman S, et al. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). *Menopause* 2020;27:1350-1356. doi: 10.1097/GME.0000000000001621
123. Fraser GL, Hoveyda HR, Clarke II, et al. The NK3 receptor antagonist ESN364 interrupts pulsatile LH secretion and moderates levels of ovarian hormones throughout the menstrual cycle. *Endocrinology* 2015;156:4214-4225. doi: 10.1210/en.2015-1409
124. McCarty MF. Isoflavones made simple—genistein's agonist activity for the beta-type estrogen receptor mediates their health benefits. *Med Hypotheses* 2006;66:1093-1114. doi: 10.1016/j.mehy.2004.11.046
125. Seth D, Poowutikul P, Pansare M, Kamat D. Food allergy: a review. *Pediatr Ann* 2020;49:e50-e58. doi: 10.3928/19382359-20191206-01
126. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. *Menopause* 2015;22:1155-1172. doi: 10.1097/gme.0000000000000546
127. Furlong ON, Parr HJ, Hodge SJ, et al. Consumption of a soy drink has no effect on cognitive function but may alleviate vasomotor symptoms in post-menopausal women: a randomised trial. *Eur J Nutr* 2020;59:755-766. doi: 10.1007/s00394-019-01942-5
128. Simpson EEA, Furlong ON, Parr HJ, et al. The effect of a randomized 12-week soy drink intervention on everyday mood in postmenopausal women. *Menopause* 2019;26:867-873. doi: 10.1097/gme.0000000000001322
129. Palma F, Fontanesi F, Facchinetti F, Cagnacci A. Acupuncture or phytoestrogens vs. (E)strogen plus progestin on menopausal symptoms. A randomized study. *Gynecol Endocrinol* 2019;35:995-998. doi: 10.1080/09513590.2019.1621835
130. Fontvieille A, Dionne IJ, Riesco E. Long-term exercise training and soy isoflavones to improve quality of life and climacteric symptoms. *Climacteric* 2017;20:233-239. doi: 10.1080/13697137.2017.1294153
131. Davinelli S, Scapagnini G, Marzatico F, Nobile V, Ferrara N, Corbi G. Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: a randomized, placebo-controlled study. *Maturitas* 2017;96:77-83. doi: 10.1016/j.maturitas.2016.11.016
132. Imhof M, Gocan A, Imhof M, Schmidt M. Soy germ extract alleviates menopausal hot flashes: placebo-controlled double-blind trial. *Eur J Clin Nutr* 2018;72:961-970. doi: 10.1038/s41430-018-0173-3
133. Kim HI, Kim MK, Lee I, Yun J, Kim EH, Seo SK. Efficacy and safety of a standardized soy and hop extract on menopausal symptoms: a 12-week, multicenter, randomized, double-blind, placebo-controlled clinical trial. *J Altern Complement Med* 2021;27:959-967. doi: 10.1089/acm.2021.0027
134. Mainini G, Passaro M, Sgambato R, et al. Phytoestrogens for menopausal vasomotor symptoms: efficacy of soybean isoflavone supplements for alleviating menopausal symptoms is positively related to hot flashes frequency. *Clin Exp Obstet Gynecol* 2017;44:521-523. doi: 10.12891/ceog4095.2017
135. Rattanantikul T, Maiprasert M, Sugkraroek P, Bumrunggert A. Efficacy and safety of nutraceutical on menopausal symptoms in post-menopausal women: a randomized, double-blind, placebo-controlled clinical trial. *J Diet Suppl* 2022;19:168-183. doi: 10.1080/19390211.2020.1853648
136. Li L, Lv Y, Xu L, Zheng Q. Quantitative efficacy of soy isoflavones on menopausal hot flashes. *Br J Clin Pharmacol* 2015;79:593-604. doi: 10.1111/bcp.12533
137. Li L, Xu L, Wu J, Dong L, Zhao S, Zheng Q. Comparative efficacy of nonhormonal drugs on menopausal hot flashes. *Eur J Clin Pharmacol* 2016;72:1051-1058. doi: 10.1007/s00228-016-2090-5
138. Newton KM, Reed SD, Uchiyama S, et al. A cross-sectional study of equol producer status and self-reported vasomotor symptoms. *Menopause* 2015;22:489-495. doi: 10.1097/GME.0000000000000363
139. Daily JW, Ko BS, Ryuk J, Liu M, Zhang W, Park S. Equol decreases hot flashes in postmenopausal women: a systematic review and meta-analysis of randomized clinical trials. *J Med Food* 2019;22:127-139. doi: 10.1089/jmf.2018.4265
140. Winther K, Rein E, Hedman C. Femal, a herbal remedy made from pollen extracts, reduces hot flashes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study. *Climacteric* 2005;8:162-170. doi: 10.1080/13697130500117987
141. Fait T, Sailer M, Rigador PA. Prospective observational study to evaluate the efficacy and safety of the pollen extract Sérélus® in the management of women with menopausal symptoms. *Gynecol Endocrinol* 2019;35:360-363. doi: 10.1080/09513590.2018.1538347
142. Lello S, Capozzi A, Xholli A, Cagnacci A; Italian Society of Menopause (SIM) and Italian Society of Gynecology of the Third Age of Women (SIGITE), and of Writing Group of the Pollen Extract in Menopause Italian Study Group. The benefits of purified cytoplasm of pollen in reducing menopausal symptoms in peri- and post-menopause: an Italian multicentre prospective observational study [published online ahead of print November 26, 2021]. *Minerva Obstet Gynecol*. doi: 10.23736/S2724-606X.21.04964-2
143. Radzinskii VE, Kuznetsova IV, Uspenskaya YB, et al. Treatment of climacteric symptoms with an ammonium succinate-based dietary supplement: a randomized, double-blind, placebo-controlled trial. *Gynecol Endocrinol* 2016;32:64-68. doi: 10.1080/09513590.2016.1232686
144. Radzinsky VE, Uspenskaya Y, Shulman LP, Kuznetsova IV. Succinate-based dietary supplement for menopausal symptoms: a pooled analysis of two identical randomized, double-blind, placebo-controlled clinical trials. *Obstet Gynecol Int* 2019;2019:1572196. doi: 10.1155/2019/1572196
145. Lim YE, Lee SY, Shin HS, et al. The effect of *Lactobacillus Acidophilus* Y11 (MENOLACTO) on improving menopausal symptoms: a randomized, double-blinded, placebo-controlled trial. *J Clin Med* 2020;9:2173. doi: 10.3390/jcm9072173
146. Heger M, Ventskovskiy BM, Borzenko I, et al. Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial. *Menopause* 2006;13:744-759. doi: 10.1097/01.gme.0000240632.08182.e4

147. Hasper I, Ventskovskiy BM, Rettenberger R, Heger PW, Riley DS, Kaszkin-Bettag M. Long-term efficacy and safety of the special extract ERr 731 of *Rheum rhoponticum* in perimenopausal women with menopausal symptoms. *Menopause* 2009;16:117-131. doi: 10.1097/GME.0b013e3181806446
148. Shah J, Chandanani S, Reddy J, et al. Evaluation of the efficacy and safety of *Rheum rhoponticum* root extract (ERr 731) for menopausal symptoms in perimenopausal Indian women: an interim analysis. *J Midlife Health* 2021; 12:108-115. doi: 10.4103/jmh.jmh_86_21
149. Kruse SO, Löhning A, Pauli GF, Winterhoff H, Nahrstedt A. Fukiic and piscidic acid esters from the rhizome of *Cimicifuga racemosa* and the in vitro estrogenic activity of fukinolic acid. *Planta Med* 1999;65:763-764. doi: 10.1055/s-2006-960862
150. Wuttke W, Jarry H, Becker T, et al. Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy? *Maturitas* 2003;44(suppl 1):S9-S20. doi: 10.1016/s0378-5122(02)00344-4
151. Mahady GB, Low Dog T, Barrett ML, et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. *Menopause* 2008;15(4 Pt 1):628-638. doi: 10.1097/gme.0b013e31816054bf
152. Leach MJ, Moore V, Black cohosh (*Cimicifuga* spp.) for menopausal symptoms. *Cochrane Database Syst Rev* 2012;2012:CD007244. doi: 10.1002/14651858.CD007244.pub2
153. Gao L, Zheng T, Xue W, et al. Efficacy and safety evaluation of *Cimicifuga foetida* extract in menopausal women. *Climacteric* 2018;21:69-74. doi: 10.1080/13697137.2017.1406913
154. Castelo-Branco C, Gambacciani M, Cano A, et al. Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms—an update on the evidence. *Climacteric* 2021;24:109-119. doi: 10.1080/13697137.2020.1820477
155. Komesaroff PA, Black CV, Cable V, Sudhir K. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. *Climacteric* 2001;4:144-150.
156. Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. *Fertil Steril* 1997;68:981-986. doi: 10.1016/s0015-0282(97)00397-x
157. Chenoy R, Hussain S, Tayob Y, et al. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. *BMJ* 1994;308:501-503. doi: 10.1136/bmj.308.6927.501
158. Lee MS, Shin BC, Yang EJ, Lim HJ, Ernst E. Maca (*Lepidium meyenii*) for treatment of menopausal symptoms: a systematic review. *Maturitas* 2011; 70:227-233. doi: 10.1016/j.maturitas.2011.07.017
159. Wiklund IK, Mattsson LA, Lindgren R, Limoni C. Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Swedish Alternative Medicine Group. *Int J Clin Pharmacol Res* 1999;19:89-99.
160. Kim HS, Yoon YJ, Lee JM, et al. A clinical study on the effect of red ginseng for postmenopausal hot flushes. *J Orient Obstet Gynecol* 2009; 22:132-139.
161. Kim SY, Seo SK, Choi YM, et al. Effects of red ginseng supplementation on menopausal symptoms and cardiovascular risk factors in postmenopausal women: a double-blind randomized controlled trial. *Menopause* 2012;19: 461-466. doi: 10.1097/gme.0b013e3182325e4b
162. Chinnappan SM, George A, Evans M, Anthony J. Efficacy of *Labisia pumila* and *Eurycoma longifolia* standardised extracts on hot flushes, quality of life, hormone and lipid profile of peri-menopausal and menopausal women: a randomised, placebo-controlled study. *Food Nutr Res* 2020;3:64. doi: doi.org/10.29219/fnr.v64.3665
163. Hajirahimkhan A, Dietz BM, Bolton JL. Botanical modulation of menopausal symptoms: mechanisms of action? *Planta Med* 2013;79:538-553. doi: 10.1055/s-0032-1328187
164. Molaie M, Darvishi B, Jafari Azar Z, Shirazi M, Amin G, Afshar S. Effects of a combination of *Nigella sativa* and *Vitex agnus-castus* with citalopram on healthy menopausal women with hot flashes: results from a subpopulation analysis. *Gynecol Endocrinol* 2019;35:58-61. doi: 10.1080/09513590.2018.1499086
165. van Die MD, Burger HG, Bone KM, Cohen MM, Teede HJ. Hypericum perforatum with *Vitex agnus-castus* in menopausal symptoms: a randomized, controlled trial. *Menopause* 2009;16:156-163. doi: 10.1097/gme.0b013e31817fa9e0
166. Rotem C, Kaplan B. Phyto-Female Complex for the relief of hot flashes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study. *Gynecol Endocrinol* 2007;23:117-122. doi: 10.1080/09513590701200900
167. Hafizi S, Abbassian A, Tabarraei M. The effect of Jazar supplement on quality of life and sexual function in postmenopausal women: a double-blind, randomized, placebo-controlled trial. *Evid Based Complement Alternat Med* 2021;8854182. doi: 10.1155/2021/8854182
168. Saberi Z, Gorji N, Memariani Z, Moeini R, Shirafkan H, Amiri M. Evaluation of the effect of *Silybum marianum* extract on menopausal symptoms: a randomized, double-blind placebo-controlled trial. *Phytother Res* 2020;34:3359-3366. doi: 10.1002/ptr.6789
169. Lucas M, Asselin G, Mérette C, Poulin MJ, Dodin S. Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. *Menopause* 2009;16:357-366. doi: 10.1097/gme.0b013e3181865386
170. Cohen LS, Joffe H, Guthrie KA, et al. Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial. *Menopause* 2014;21: 347-354. doi: 10.1097/GME.0b013e31829e40b8
171. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. *J Clin Oncol* 1998; 16:495-500. doi: 10.1200/JCO.1998.16.2.495
172. Ziaei S, Kazemnejad A, Zareai M. The effect of vitamin E on hot flashes in menopausal women. *Gynecol Obstet Invest* 2007;64:204-207. doi: 10.1159/000106491
173. Ataei-Almanghadim K, Farshbaf-Khalili A, Ostadrahimi AR, Shaseb E, Mirghafourvand M. The effect of oral capsule of curcumin and vitamin E on the hot flashes and anxiety in postmenopausal women: a triple blind randomised controlled trial. *Complement Ther Med* 2020;48:102267. doi: doi.org/10.1016/j.ctim.2019.102267
174. Dahlgren MK, El-Abboud C, Lambros AM, Sagar KA, Smith RT, Gruber SA. A survey of medical cannabis use during perimenopause and postmenopause. *Menopause* 2022;29:1028-1036. doi: 10.1097/GME.0000000000002018
175. Mejia-Gomez J, Phung N, Philippopoulos E, Murphy KE, Wolfman W. The impact of cannabis use on vasomotor symptoms, mood, insomnia and sexuality in perimenopausal and postmenopausal women: a systematic review. *Climacteric* 2021;24:572-576. doi: 10.1080/13697137.2021.1898581
176. Chien TJ, Hsu CH, Liu CY, Fang CJ. Effect of acupuncture on hot flush and menopause symptoms in breast cancer—a systematic review and meta-analysis. *PLoS One* 2017;12:e0180918. doi: 10.1371/journal.pone.0180918
177. Chien TJ, Liu CY, Fang CJ, Kuo CY. The maintenance effect of acupuncture on breast cancer-related menopause symptoms: a systematic review. *Climacteric* 2020;23:130-139. doi: 10.1080/13697137.2019.1664460
178. Li T, Zhang Y, Cheng Q, et al. Quantitative study on the efficacy of acupuncture in the treatment of menopausal hot flashes and its comparison with nonhormonal drugs. *Menopause* 2021;28:564-572. doi: 10.1097/GME.0000000000001767
179. Liu Z, Ai Y, Wang W, et al. Acupuncture for symptoms in menopause transition: a randomized controlled trial. *Am J Obstet Gynecol* 2018;219: 373.e1-373.e10. doi: 10.1016/j.ajog.2018.08.019
180. Befus D, Coeytaux RR, Goldstein KM, et al. Management of menopause symptoms with acupuncture: an umbrella systematic review and meta-analysis. *J Altern Complement Med* 2018;24:314-323. doi: 10.1089/acm.2016.0408
181. Zhong Z, Dong H, Wang H, Huang Y, Huang D, Huang G. Electroacupuncture for the treatment of perimenopausal syndrome: a systematic review and meta-analysis of randomized controlled trials. *Acupunct Med* 2022;40:111-122. doi: 10.1177/09645284211055742
182. Higa K, Hirata K, Hirota K, Nitahara K, Shono S. Retropharyngeal hematoma after stellate ganglion block: Analysis of 27 patients reported in the literature. *Anesthesiology* 2006;105:1238-1245. doi: 10.1097/0000542-200612000-00024
183. Walega DR, Rubin LH, Banuvar S, Shulman LP, Maki PM. Effects of stellate ganglion block on VMS: findings from a randomized controlled clinical trial in postmenopausal women. *Menopause* 2014;21:807-814. doi: 10.1097/GME.0000000000000194
184. Lipov EG, Joshi JR, Xie H, Slavina KV. Updated findings on the effects of stellate-ganglion block on hot flashes and night awakenings. *Lancet Oncol* 2008;9:819-820. doi: 10.1016/S1470-2045(08)70218-3
185. Pachman DR, Barton D, Carns PE, et al. Pilot evaluation of a stellate ganglion block for the treatment of hot flashes. *Support Care Cancer* 2011;19:941-947. doi: 10.1007/s00520-010-0907-9
186. Haest K, Kumar A, Van Calster B, et al. Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up. *Ann Oncol* 2012;23:1449-1454. doi: 10.1093/annonc/mdr478
187. van Gastel P, Kallewaard JW, van der Zanden M, de Boer H. Stellate-ganglion block as a treatment for severe postmenopausal flushing. *Climacteric* 2013;16:41-47. doi: 10.3109/13697137.2012.709889
188. Rahimzadeh P, Imani F, Nafissi N, Ebrahimi B, Faiz SHR. Comparison of the effects of stellate ganglion block and paroxetine on hot flashes and

NAMS POSITION STATEMENT

- sleep disturbance in breast cancer survivors. *Cancer Manag Res* 2018;10:4831-4837. doi: 10.2147/CMAR.S173511
189. Tegeler CL, Shaltout HA, Lee SW, Simpson SL, Gerdes L, Tegeler CH. High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) improves symptoms and autonomic function for insomnia: a randomized, placebo-controlled clinical trial. *Brain Behav*. 2020;10:e01826. doi: 10.1002/brb3.1826
190. Lee SW, Laurienti PJ, Burdette JH, et al. Functional brain network changes following use of an allostatic, closed-loop, acoustic stimulation neurotechnology for military-related traumatic stress. *J Neuroimaging* 2019;29:70-78. doi: 10.1111/jon.12571
191. Tegeler CH, Tegeler CL, Cook JF, Lee SW, Pajewski NM. Reduction in menopause-related symptoms associated with use of a noninvasive neurotechnology for autocalibration of neural oscillations. *Menopause* 2015;22:650-655. doi: 10.1097/GME.0000000000000422
192. Goto V, Frange C, Andersen ML, Júnior JM, Tufik S, Hachul H. Chiropractic intervention in the treatment of postmenopausal climacteric symptoms and insomnia: a review. *Maturitas* 2014;78:3-7. doi: 10.1016/j.maturitas.2014.02.004

The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society has been designated a CME activity for all NAMS members. NAMS members should log in to the NAMS website, www.menopause.org, and then select Online CME in the Member Center. CME credit will be available from June 1, 2023, to June 1, 2024.